Self-propagation of pathogenic protein aggregates in ne

Nature

501, 45-51

DOI: 10.1038/nature12481

Citation Report

#	Article	IF	Citations
1	Drug resistance confounding prion therapeutics. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4160-9.	3.3	120
2	Transmission of multiple system atrophy prions to transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19555-19560.	3.3	359
3	Amyotrophic lateral sclerosisâ€"a model of corticofugal axonal spread. Nature Reviews Neurology, 2013, 9, 708-714.	4.9	432
4	Protein Transmission, Seeding and Degradation: Key Steps for Î±-Synuclein Prion-Like Propagation. Experimental Neurobiology, 2014, 23, 324-336.	0.7	45
5	p150glued-Associated Disorders Are Caused by Activation of Intrinsic Apoptotic Pathway. PLoS ONE, 2014, 9, e94645.	1.1	14
6	Shaking Alone Induces De Novo Conversion of Recombinant Prion Proteins to Î²-Sheet Rich Oligomers and Fibrils. PLoS ONE, 2014, 9, e98753.	1.1	33
7	Immunological Activity Difference between Native Calreticulin Monomers and Oligomers. PLoS ONE, 2014, 9, e105502.	1.1	7
8	Biochemical Assessment of Precuneus and Posterior Cingulate Gyrus in the Context of Brain Aging and Alzheimerâ€™s Disease. PLoS ONE, 2014, 9, e105784.	1.1	16
9	Self-Propagative Replication of AÎ² Oligomers Suggests Potential Transmissibility in Alzheimer Disease. PLoS ONE, 2014, 9, e111492.	1.1	29
10	Hijacking PrPc-dependent signal transduction: when prions impair AÎ² clearance. Frontiers in Aging Neuroscience, 2014, 6, 25.	1.7	20
11	Selective alterations of neurons and circuits related to early memory loss in AlzheimerÃ¢â‚¬â„¢s disease. Frontiers in Neuroanatomy, 2014, 8, 38.	0.9	72
12	Role of CXCL10 in central nervous system inflammation. International Journal of Interferon, Cytokine and Mediator Research, 0, , 1.	1.1	24
13	Self-propagating amyloid as a critical regulator for diverse cellular functions. Journal of Biochemistry, 2014, 155, 345-351.	0.9	11
14	Multitarget ligands and theranostics: sharpening the medicinal chemistry sword against prion diseases. Future Medicinal Chemistry, 2014, 6, 1017-1029.	1.1	7
15	Applying the tools of chemistry (mass spectrometry and covalent modification by small molecule) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.9	10
16	Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2014, 2, 146.	2.4	79
17	AÎ² seeds resist inactivation by formaldehyde. Acta Neuropathologica, 2014, 128, 477-484.	3.9	58
18	Models of Î²-amyloid induced Tau-pathology: the long and â€œfoldedâ€•road to understand the mechanism. Molecular Neurodegeneration, 2014, 9, 51.	4.4	220

#	Article	IF	Citations
19	Î²-amyloid induces a dying-back process and remote trans-synaptic alterations in a microfluidic-based reconstructed neuronal network. Acta Neuropathologica Communications, 2014, 2, 145.	2.4	36
20	Direct Evidence for Self-Propagation of Different Amyloid-Î² Fibril Conformations. Neurodegenerative Diseases, 2014, 14, 151-159.	0.8	17
21	Neurodegenerative disorders: Dysregulation of a carefully maintained balance?. Experimental Gerontology, 2014, 58, 279-291.	1.2	17
22	Aggregation Properties of the Small Nuclear Ribonucleoprotein U1-70K in Alzheimer Disease. Journal of Biological Chemistry, 2014, 289, 35296-35313.	1.6	42
23	Evidence That Bank Vole PrP Is a Universal Acceptor for Prions. PLoS Pathogens, 2014, 10, e1003990.	2.1	92
24	Epidemic Spreading Model to Characterize Misfolded Proteins Propagation in Aging and Associated Neurodegenerative Disorders. PLoS Computational Biology, 2014, 10, e1003956.	1.5	151
25	Prions of Vertebratesâ˜†. , 2014, , .		0
26	Chronic Traumatic Encephalopathy. Progress in Neurological Surgery, 2014, 28, 38-49.	1.3	94
27	An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis. Expert Opinion on Investigational Drugs, 2014, 23, 1239-1251.	1.9	47
28	Prion-like polymerization as a signaling mechanism. Trends in Immunology, 2014, 35, 622-630.	2.9	31
29	Molecular neurodegeneration: basic biology and disease pathways. Molecular Neurodegeneration, 2014, 9, 34.	4.4	4
30	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Science Translational Medicine, 2014, 6, 243ra86.	5.8	600
31	The New Neurometabolic Cascade of Concussion. Neurosurgery, 2014, 75, S24-S33.	0.6	934
32	Multiple Factors Contribute to the Peripheral Induction of Cerebral Â-Amyloidosis. Journal of Neuroscience, 2014, 34, 10264-10273.	1.7	76
33	ADSC Therapy in Neurodegenerative Disorders. Cell Transplantation, 2014, 23, 549-557.	1.2	51
34	Looked at Life from Both Sides Now. Life, 2014, 4, 887-902.	1.1	20
37	High-throughput Analysis of Ultrasonication-forced Amyloid Fibrillation Reveals the Mechanism Underlying the Large Fluctuation in the Lag Time. Journal of Biological Chemistry, 2014, 289, 27290-27299.	1.6	39
38	Spreading of amyloid-Î² peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance. Neurobiology of Disease, 2014, 65, 82-92.	2.1	135

#	Article	IF	Citations
39	Protein aggregation and prionopathies. Pathologie Et Biologie, 2014, 62, 162-168.	2.2	23
40	Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathologica, 2014, 127, 423-439.	3.9	237
41	Heat of supersaturation-limited amyloid burst directly monitored by isothermal titration calorimetry. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 6654-6659.	3.3	82
42	Cyclic Peptides as Inhibitors of Amyloid Fibrillation. Chemistry - A European Journal, 2014, 20, 2410-2419.	1.7	44
43	Prion-like aggregation of mutant p53 in cancer. Trends in Biochemical Sciences, 2014, 39, 260-267.	3.7	167
44	The amyloid state and its association with protein misfolding diseases. Nature Reviews Molecular Cell Biology, 2014, 15, 384-396.	16.1	1,894
45	Amyloidogenic Î±-synuclein seeds do not invariably induce rapid, widespread pathology in mice. Acta Neuropathologica, 2014, 127, 645-665.	3.9	103
46	Kinetic Intermediates in Amyloid Assembly. Journal of the American Chemical Society, 2014, 136, 15146-15149.	6.6	85
47	The therapeutic potential of chemical chaperones in protein folding diseases. Prion, 2014, 8, 197-202.	0.9	194
48	Degeneration of amyloid-ÃŸ fibrils caused by exposure to low-temperature atmospheric-pressure plasma in aqueous solution. Applied Physics Letters, 2014, 104, .	1.5	18
49	Targeting prion propagation using peptide constructs with signal sequence motifs. Archives of Biochemistry and Biophysics, 2014, 564, 254-261.	1.4	17
50	Orientation of aromatic residues in amyloid cores: Structural insights into prion fiber diversity. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17158-17163.	3.3	12
51	Rebels with a cause: molecular features and physiological consequences of yeast prions. FEMS Yeast Research, 2014, 14, 136-147.	1.1	47
52	Highly potent soluble amyloid-Î² seeds in human Alzheimer brain but not cerebrospinal fluid. Brain, 2014, 137, 2909-2915.	3.7	61
53	Specific aromatic foldamers potently inhibit spontaneous and seeded AÎ²42 and AÎ²43 fibril assembly. Biochemical Journal, 2014, 464, 85-98.	1.7	13
54	Has Darwin's Pangenesis Been Rediscovered?. BioScience, 2014, 64, 1037-1041.	2.2	2
55	Brain Injection of Î±-Synuclein Induces Multiple Proteinopathies, Gliosis, and a Neuronal Injury Marker. Journal of Neuroscience, 2014, 34, 12368-12378.	1.7	115
56	Human DNA tumor viruses generate alternative reading frame proteins through repeat sequence recoding. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4342-E4349.	3.3	18

#	Article	IF	Citations
57	Investigating the Intrinsic Aggregation Potential of Evolutionarily Conserved Segments in p53. Biochemistry, 2014, 53, 5995-6010.	1.2	51
58	Application of biomaterials for the detection of amyloid aggregates. Biomaterials Science, 2014, 2, 951-955.	2.6	12
59	Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked. Nature Communications, 2014, 5, 4347.	5.8	126
60	Mouse Models for Studying the Formation and Propagation of Prions. Journal of Biological Chemistry, 2014, 289, 19841-19849.	1.6	83
61	Mass Spectrometry Methods for Studying Structure and Dynamics of Biological Macromolecules. Analytical Chemistry, 2014, 86, 213-232.	3.2	114
62	Is there a risk of prion-like disease transmission by Alzheimer- or Parkinson-associated protein particles?. Acta Neuropathologica, 2014, 128, 463-476.	3.9	62
63	Successes and Challenges in Phenotype-Based Lead Discovery for Prion Diseases. Journal of Medicinal Chemistry, 2014, 57, 6919-6929.	2.9	22
64	Functional screening in Drosophila reveals the conserved role of REEP1 in promoting stress resistance and preventing the formation of Tau aggregates. Human Molecular Genetics, 2014, 23, 6762-6772.	1.4	17
65	Alzheimer Peptides Aggregate into Transient Nanoglobules That Nucleate Fibrils. Biochemistry, 2014, 53, 6302-6308.	1.2	32
66	TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. Acta Neuropathologica, 2014, 128, 423-437.	3.9	203
67	Golgi fragmentation precedes neuromuscular denervation and is associated with endosome abnormalities in SOD1-ALS mouse motor neurons. Acta Neuropathologica Communications, 2014, 2, 38.	2.4	43
68	Serial propagation of distinct strains of AÎ² prions from Alzheimerâ€™s disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10323-10328.	3.3	247
69	Spatial Propagation of Protein Polymerization. Physical Review Letters, 2014, 112, 098101.	2.9	20
70	Beyond Expectations. International Review of Cell and Molecular Biology, 2014, 311, 265-306.	1.6	72
71	Selective increase of in vivo firing frequencies in <scp>DA SN</scp> neurons after proteasome inhibition in the ventral midbrain. European Journal of Neuroscience, 2014, 40, 2898-2909.	1.2	20
72	The use of nanopore analysis for discovering drugs which bind to Î±-synuclein for treatment of Parkinson's disease. European Journal of Medicinal Chemistry, 2014, 88, 42-54.	2.6	37
73	Supersaturation-limited Amyloid Fibrillation of Insulin Revealed by Ultrasonication. Journal of Biological Chemistry, 2014, 289, 18228-18238.	1.6	45
74	Structureâ€“Activity Relationship Study around Guanabenz Identifies Two Derivatives Retaining Antiprion Activity but Having Lost Î±2-Adrenergic Receptor Agonistic Activity. ACS Chemical Neuroscience, 2014, 5, 1075-1082.	1.7	25

#	Article	IF	Citations
75	Intramuscular injection of Î±-synuclein induces CNS Î±-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10732-10737.	3.3	277
76	Unraveling the mechanism of cell death induced by chemical fibrils. Nature Chemical Biology, 2014, 10, 969-976.	3.9	43
77	Androgens affect muscle, motor neuron, and survival in a mouse model of SOD1-related amyotrophic lateral sclerosis. Neurobiology of Aging, 2014, 35, 1929-1938.	1.5	31
78	SQSTM1 mutations â€“ Bridging Paget disease of bone and ALS/FTLD. Experimental Cell Research, 2014, 325, 27-37.	1.2	123
79	Somatic Mosaicism and Disease. Current Biology, 2014, 24, R577-R581.	1.8	50
80	The Intersection of Amyloid Beta and Tau at Synapses in Alzheimerâ€™s Disease. Neuron, 2014, 82, 756-771.	3.8	862
81	Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1556-1566.	1.8	161
82	The disease intersection of susceptibility and exposure: Chemical exposures and neurodegenerative disease risk. Alzheimer's and Dementia, 2014, 10, S213-25.	0.4	72
83	Polyanion binding accelerates the formation of stable and lowâ€toxic aggregates of <scp>ALS</scp>â€linked <scp>SOD</scp>1 mutant <scp>A</scp>4<scp>V</scp>. Proteins: Structure, Function and Bioinformatics, 2014, 82, 3356-3372.	1.5	11
84	Single Mutations in Tau Modulate the Populations of Fibril Conformers through Seed Selection. Angewandte Chemie - International Edition, 2014, 53, 1590-1593.	7.2	38
86	Theme and variations: evolutionary diversification of the HET-s functional amyloid motif. Scientific Reports, 2015, 5, 12494.	1.6	29
87	Forebrain microglia from wild-type but not adult 5xFAD mice prevent amyloid-Î² plaque formation in organotypic hippocampal slice cultures. Scientific Reports, 2015, 5, 14624.	1.6	82
88	Ubiquitin ligase ITCH recruitment suppresses the aggregation and cellular toxicity of cytoplasmic misfolded proteins. Scientific Reports, 2014, 4, 5077.	1.6	28
89	Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimerâ€™s Disease Mice. Journal of Alzheimer's Disease, 2015, 46, 123-136.	1.2	34
90	Transient Î²-hairpin formation in Î±-synuclein monomer revealed by coarse-grained molecular dynamics simulation. Journal of Chemical Physics, 2015, 143, 243142.	1.2	73
91	Investigating the Spreading and Toxicity of Prion-like Proteins Using the Metazoan Model Organism C. elegans. Journal of Visualized Experiments, 2015, , 52321.	0.2	125
92	Peripherally Applied Synthetic Tetrapeptides HAEE and RADD Slow Down the Development of Cerebral Î²-Amyloidosis in AÎ²PP/PS1 Transgenic Mice. Journal of Alzheimer's Disease, 2015, 46, 849-853.	1.2	14
93	A systematic investigation of production of synthetic prions from recombinant prion protein. Open Biology, 2015, 5, 150165.	1.5	39

#	Article	IF	Citations
94	Propagation of Pathology through Brain Networks in Neurodegenerative Diseases: From Molecules to Clinical Phenotypes. CNS Neuroscience and Therapeutics, 2015, 21, 754-767.	1.9	38
95	Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. EMBO Journal, 2015, 34, 3028-3041.	3.5	112
96	Reduced miR-512 and the Elevated Expression of Its Targets cFLIP and MCL1 Localize to Neurons With Hyperphosphorylated Tau Protein in Alzheimer Disease. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 615-623.	0.6	24
97	Preclinical Validation of Multilevel Intraparenchymal Stem Cell Therapy in the Porcine Spinal Cord. Neurosurgery, 2015, 77, 604-612.	0.6	21
98	Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases. Journal of Parkinson's Disease, 2015, 5, 217-227.	1.5	107
99	Argyrophilic grain disease: An underestimated tauopathy. Dementia E Neuropsychologia, 2015, 9, 2-8.	0.3	46
100	Unfolded Protein Response and Macroautophagy in Alzheimerâ€™s, Parkinsonâ€™s and Prion Diseases. Molecules, 2015, 20, 22718-22756.	1.7	31
101	On the central role of brain connectivity in neurodegenerative disease progression. Frontiers in Aging Neuroscience, 2015, 7, 90.	1.7	53
102	Expanding the Repertoire of Biomarkers for Alzheimerâ€™s Disease: Targeted and Non-targeted Approaches. Frontiers in Neurology, 2015, 6, 256.	1.1	16
103	Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease. Frontiers in Neuroscience, 2015, 9, 59.	1.4	97
104	Transmissibility of H-Type Bovine Spongiform Encephalopathy to Hamster PrP Transgenic Mice. PLoS ONE, 2015, 10, e0138977.	1.1	5
105	The mTOR Inhibitor Rapamycin Mitigates Perforant Pathway Neurodegeneration and Synapse Loss in a Mouse Model of Early-Stage Alzheimer-Type Tauopathy. PLoS ONE, 2015, 10, e0142340.	1.1	117
106	Network structure of brain atrophy in de novo Parkinson's disease. ELife, 2015, 4, .	2.8	187
107	A novel and rapid method for obtaining high titre intact prion strains from mammalian brain. Scientific Reports, 2015, 5, 10062.	1.6	51
108	Type 2 diabetes as a protein misfolding disease. Trends in Molecular Medicine, 2015, 21, 439-449.	3.5	255
109	A naturally occurring variant of the human prion protein completely prevents prion disease. Nature, 2015, 522, 478-481.	13.7	144
110	Efficient inhibition of infectious prions multiplication and release by targeting the exosomal pathway. Cellular and Molecular Life Sciences, 2015, 72, 4409-4427.	2.4	47
111	Monogenic causes of stroke: now and the future. Journal of Neurology, 2015, 262, 2601-2616.	1.8	55

#	Article	IF	Citations
112	Progressive Aggregation of Alpha-Synuclein and Selective Degeneration of Lewy Inclusion-Bearing Neurons in a Mouse Model of Parkinsonism. Cell Reports, 2015, 10, 1252-1260.	2.9	185
113	Limited Proteolysis Reveals That Amyloids from the 3D Domain-Swapping Cystatin B Have a Non-Native Î²-Sheet Topology. Journal of Molecular Biology, 2015, 427, 2418-2434.	2.0	10
114	The Use of Cerebrospinal Fluid and Neuropathologic Studies in Neuropsychiatry Practice and Research. Psychiatric Clinics of North America, 2015, 38, 309-322.	0.7	12
115	Defining the Dynamic Conformational Networks of Crossâ€Îβ Peptide Assembly. Israel Journal of Chemistry, 2015, 55, 763-769.	1.0	16
116	Carbonization of a stable Î²-sheet-rich silk protein into a pseudographitic pyroprotein. Nature Communications, 2015, 6, 7145.	5.8	192
117	Synaptic Contacts Enhance Cell-to-Cell Tau Pathology Propagation. Cell Reports, 2015, 11, 1176-1183.	2.9	206
118	cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E7176-85.	3.3	198
119	Deep Brain Stimulation of the Nucleus Basalis of Meynert in Early Stage of Alzheimer's Dementia. Brain Stimulation, 2015, 8, 838-839.	0.7	60
120	Controlling in Vitro Insulin Amyloidosis with Stable Peptide Conjugates: A Combined Experimental and Computational Study. Journal of Physical Chemistry B, 2015, 119, 15395-15406.	1.2	30
121	Downregulation of Î²-Soluble N-Ethylmaleimide-Sensitive Factor Attachment Protein: Proteomics-Based Identification in Early-Stage Prion Disease. Neurodegenerative Diseases, 2015, 15, 193-201.	0.8	0
122	Loss of intramolecular electrostatic interactions and limited conformational ensemble may promote self-association ofcis-tau peptide. Proteins: Structure, Function and Bioinformatics, 2015, 83, 436-444.	1.5	3
123	Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathologica, 2015, 129, 469-491.	3.9	218
124	Propagation of aggregated p53: Cross-reaction and coaggregation vs. seeding. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2443-2448.	3.3	59
125	Formaldehyde-fixed brain tissue from spontaneously ill Î±-synuclein transgenic mice induces fatal Î±-synucleinopathy in transgenic hosts. Acta Neuropathologica, 2015, 129, 157-159.	3.9	34
126	Progression of Seedâ€Induced <scp>A</scp>Î² Deposition within the Limbic Connectome. Brain Pathology, 2015, 25, 743-752.	2.1	45
127	Lab-on-a-brain: Implantable micro-optical fluidic devices for neural cell analysis in vivo. Scientific Reports, 2014, 4, 6721.	1.6	32
128	Network Diffusion Model of Progression Predicts Longitudinal Patterns of Atrophy and Metabolism in Alzheimerâ€™s Disease. Cell Reports, 2015, 10, 359-369.	2.9	177
129	Substitution of Proline32 by Î±-Methylproline Preorganizes Î²2-Microglobulin for Oligomerization but Not for Aggregation into Amyloids. Journal of the American Chemical Society, 2015, 137, 2524-2535.	6.6	17

#	Article	IF	Citations
130	A new prion disease: relationship with central and peripheral amyloidoses. Nature Reviews Neurology, 2015, 11, 90-97.	4.9	41
131	Spreading of pathology in neurodegenerative diseases: a focus on human studies. Nature Reviews Neuroscience, 2015, 16, 109-120.	4.9	611
132	From nucleation to widespread propagation: A prion-like concept for ALS. Virus Research, 2015, 207, 94-105.	1.1	53
133	Mechanisms of Molecular Mimicry Involving the Microbiota in Neurodegeneration. Journal of Alzheimer's Disease, 2015, 45, 349-362.	1.2	259
134	Transgenic Fatal Familial Insomnia Mice Indicate Prion Infectivity-Independent Mechanisms of Pathogenesis and Phenotypic Expression of Disease. PLoS Pathogens, 2015, 11, e1004796.	2.1	61
135	Trafficking and degradation pathways in pathogenic conversion of prions and prion-like proteins in neurodegenerative diseases. Virus Research, 2015, 207, 146-154.	1.1	15
136	Dynamic Proteomics. Methods in Enzymology, 2015, 561, 219-276.	0.4	57
137	Stimulated emission depletion microscopy to study amyloid fibril formation. , 2015, , .		8
138	Alzheimerâ€™s and Parkinsonâ€™s diseases: The prion concept in relation to assembled AÎ², tau, and Î±-synuclein. Science, 2015, 349, 1255555.	6.0	753
139	Molecular-level insights of early-stage prion protein aggregation on mica and gold surface determined by AFM imaging and molecular simulation. Colloids and Surfaces B: Biointerfaces, 2015, 135, 371-378.	2.5	24
140	AÎ² â€œStretching-and-Packingâ€•Cross-Seeding Mechanism Can Trigger Tau Protein Aggregation. Journal of Physical Chemistry Letters, 2015, 6, 3276-3282.	2.1	42
141	Imaging stress. Cell Stress and Chaperones, 2015, 20, 867-874.	1.2	5
142	Thioflavin T templates amyloid Î²(1â€“40) conformation and aggregation pathway. Biophysical Chemistry, 2015, 206, 1-11.	1.5	35
143	Structural, morphological, and functional diversity of amyloid oligomers. FEBS Letters, 2015, 589, 2640-2648.	1.3	150
144	The CPEB3 Protein Is a Functional Prion that Interacts with the Actin Cytoskeleton. Cell Reports, 2015, 11, 1772-1785.	2.9	109
145	All-Aqueous Electrosprayed Emulsion for Templated Fabrication of Cytocompatible Microcapsules. ACS Applied Materials & Interfaces, 2015, 7, 13925-13933.	4.0	105
146	Overview of Neurodegenerative Disorders and Susceptibility Factors in Neurodegenerative Processes. , 2015, , 197-210.		1
147	<scp>TDP</scp>â€43 in amyotrophic lateral sclerosis â€“ is it a prion disease?. European Journal of Neurology, 2015, 22, 753-761.	1.7	38

#	Article	IF	Citations
148	Structural Studies of Truncated Forms of the Prion Protein PrP. Biophysical Journal, 2015, 108, 1548-1554.	0.2	25
149	Propagation of dysbindin-1B aggregates: Exosome-mediated transmission of neurotoxic deposits. Neuroscience, 2015, 291, 301-316.	1.1	22
150	Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimerâ€™s disease or corticobasal degeneration brains. Acta Neuropathologica, 2015, 129, 221-237.	3.9	211
151	Amyloid-Î² Activates Microglia and Regulates Protein Expression in a Manner Similar to Prions. Journal of Molecular Neuroscience, 2015, 56, 509-518.	1.1	18
152	Stable self-assembled nanostructured hen egg white lysozyme exhibits strong anti-proliferative activity against breast cancer cells. Colloids and Surfaces B: Biointerfaces, 2015, 130, 237-245.	2.5	49
153	Layers of structure and function in protein aggregation. Nature Chemical Biology, 2015, 11, 373-377.	3.9	35
154	Assembly and Disassembly of Protein Aggregates. , 2015, , 229-276.		0
155	To rise and to fall: functional connectivity in cognitively normal and cognitively impaired patients with Parkinson's disease. Neurobiology of Aging, 2015, 36, 1727-1735.	1.5	119
156	Amyloid Polymorphism: Structural Basis and Neurobiological Relevance. Neuron, 2015, 86, 632-645.	3.8	347
157	Neurodegenerative Diseases: Expanding the Prion Concept. Annual Review of Neuroscience, 2015, 38, 87-103.	5.0	278
158	Engineering enhanced protein disaggregases for neurodegenerative disease. Prion, 2015, 9, 90-109.	0.9	68
159	Identification of a Compound That Disrupts Binding of Amyloid-Î² to the Prion Protein Using a Novel Fluorescence-based Assay. Journal of Biological Chemistry, 2015, 290, 17020-17028.	1.6	36
160	Use of a 2-aminothiazole to Treat Chronic Wasting Disease in Transgenic Mice. Journal of Infectious Diseases, 2015, 212, S17-S25.	1.9	19
161	Neurodegenerative Disorders as Systemic Diseases. , 2015, , .		2
162	Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells. Journal of Neuroscience, 2015, 35, 14234-14250.	1.7	186
163	Iatrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years. Brain, 2015, 138, 3386-3399.	3.7	92
165	Huntingtonâ€™s disease cerebrospinal fluid seeds aggregation of mutant huntingtin. Molecular Psychiatry, 2015, 20, 1286-1293.	4.1	45
166	Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer's disease. Chemical Communications, 2015, 51, 13434-13450.	2.2	191

#	Article	IF	Citations
167	Transcranial Direct Current Stimulation Against Sudden Unexpected Death in Epilepsy: Press That Button Again, Please. Brain Stimulation, 2015, 8, 839-840.	0.7	5
168	A cascade of protein aggregation bombards mitochondria for neurodegeneration and apoptosis under WWOX deficiency. Cell Death and Disease, 2015, 6, e1881-e1881.	2.7	17
169	Sensitivity-Enhanced NMR Reveals Alterations in Protein Structure by Cellular Milieus. Cell, 2015, 163, 620-628.	13.5	126
170	Liquid demixing of intrinsically disordered proteins is seeded by poly(ADP-ribose). Nature Communications, 2015, 6, 8088.	5.8	463
171	In vitro fibrillization of Alzheimerâ€™s amyloid-Î² peptide (1-42). AIP Advances, 2015, 5, .	0.6	48
172	A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation. Cell, 2015, 162, 1066-1077.	13.5	2,182
173	Amyloid-Î² pathology induced in humans. Nature, 2015, 525, 193-194.	13.7	43
174	Persistence of AÎ² seeds in APP null mouse brain. Nature Neuroscience, 2015, 18, 1559-1561.	7.1	51
175	Integrated multimodal imaging in neurodegenerative disease. Lancet Neurology, The, 2015, 14, 973-975.	4.9	3
176	Targeting protein aggregation for the treatment of degenerative diseases. Nature Reviews Drug Discovery, 2015, 14, 759-780.	21.5	338
177	Transcriptional mutagenesis by 8-oxodG in Î±-synuclein aggregation and the pathogenesis of Parkinsonâ€™s disease. Experimental and Molecular Medicine, 2015, 47, e179-e179.	3.2	27
178	Drugs That Bind to Î±-Synuclein: Neuroprotective or Neurotoxic?. ACS Chemical Neuroscience, 2015, 6, 1930-1940.	1.7	29
179	SOD1 protein aggregates stimulate macropinocytosis in neurons to facilitate their propagation. Molecular Neurodegeneration, 2015, 10, 57.	4.4	68
180	Transport of cargo from periphery to brain by circulating monocytes. Brain Research, 2015, 1622, 328-338.	1.1	14
181	HSP70 protects human neuroblastoma cells from apoptosis and oxidative stress induced by amyloid peptide isoAsp7-AÎ²(1â€“42). Cell Death and Disease, 2015, 6, e1977-e1977.	2.7	25
183	Ultrasonication-dependent formation and degradation of Î±-synuclein amyloid fibrils. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 209-217.	1.1	21
184	Peptide sequences converting polyglutamine into a prion in yeast. FEBS Journal, 2015, 282, 477-490.	2.2	0
185	Calcium binding to gatekeeper residues flanking aggregation-prone segments underlies non-fibrillar amyloid traits in superoxide dismutase 1 (SOD1). Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 118-126.	1.1	13

#	Article	IF	Citations
186	In search of innovative therapeutics for neuropsychiatric disorders: The case of neurodegenerative diseases. Annales Pharmaceutiques Francaises, 2015, 73, 3-12.	0.4	9
187	Selectivity of Aggregation-Determining Interactions. Journal of Molecular Biology, 2015, 427, 236-247.	2.0	25
188	The diversity and relationship of prion protein self-replicating states. Virus Research, 2015, 207, 113-119.	1.1	24
189	Parkinsonâ€™s Disease (Pathogenesis and Its Management): An Overview. , 2016, 06, .		0
190	What Lies Ahead?. , 2016, , 313-337.		0
192	Etiologic Framework for the Study of Neurodegenerative Disorders as Well as Vascular and Metabolic Comorbidities on the Grounds of Shared Epidemiologic and Biologic Features. Frontiers in Aging Neuroscience, 2016, 8, 138.	1.7	6
193	CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease. Frontiers in Neuroscience, 2016, 10, 243.	1.4	92
194	Multifaceted Role of Sialylation in Prion Diseases. Frontiers in Neuroscience, 2016, 10, 358.	1.4	54
195	Molecular Mechanisms in the Pathogenesis of Alzheimerâ€™s disease and Tauopathies-Prion-Like Seeded Aggregation and Phosphorylation. Biomolecules, 2016, 6, 24.	1.8	53
196	Focus on Extracellular Vesicles: Exosomes and Their Role in Protein Trafficking and Biomarker Potential in Alzheimerâ€™s and Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2016, 17, 173.	1.8	196
197	Focus on Extracellular Vesicles: Physiological Role and Signalling Properties of Extracellular Membrane Vesicles. International Journal of Molecular Sciences, 2016, 17, 171.	1.8	231
198	Arterial spin labeling perfusion predicts longitudinal decline in semantic variant primary progressive aphasia. Journal of Neurology, 2016, 263, 1927-1938.	1.8	23
199	Synergistic stress exacerbation in hippocampal neurons: Evidence favoring the dualâ€hit hypothesis of neurodegeneration. Hippocampus, 2016, 26, 980-994.	0.9	20
200	Axonal TDPâ€43 aggregates in sporadic amyotrophic lateral sclerosis. Neuropathology and Applied Neurobiology, 2016, 42, 561-572.	1.8	10
201	Heterochromatin aggregation during DNA elimination in Tetrahymena is facilitated by a prion-like protein. Journal of Cell Science, 2017, 130, 480-489.	1.2	22
202	Role of polysaccharide and lipid in lipopolysaccharide induced prion protein conversion. Prion, 2016, 10, 466-483.	0.9	7
203	The Presence of Select Tau Species in Human Peripheral Tissues and Their Relation to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 345-356.	1.2	56
204	Proteopathic Strains and the Heterogeneity of Neurodegenerative Diseases. Annual Review of Genetics, 2016, 50, 329-346.	3.2	53

#	Article	IF	Citations
205	Structural basis of synaptic vesicle assembly promoted by Î±-synuclein. Nature Communications, 2016, 7, 12563.	5.8	203
206	Endoplasmic Reticulum-Associated Degradation and Protein Quality Control. , 2016, , 596-611.		4
207	TDP-43 or FUS-induced misfolded human wild-type SOD1 can propagate intercellularly in a prion-like fashion. Scientific Reports, 2016, 6, 22155.	1.6	65
208	The Brainâ€™s Structural Connectome Mediates the Relationship between Regional Neuroimaging Biomarkers inÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 1639-1657.	1.2	18
209	Transmission of Neurodegenerative Disorders Through Blood Transfusion. Annals of Internal Medicine, 2016, 165, 316.	2.0	40
210	Targets and Strategies Toward the Development of Alzheimer Therapeutics. Topics in Medicinal Chemistry, 2016, , 1-25.	0.4	0
211	Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons. Scientific Reports, 2016, 6, 34904.	1.6	67
212	Structural Ensembles of Membrane-bound Î±-Synuclein Reveal the Molecular Determinants of Synaptic Vesicle Affinity. Scientific Reports, 2016, 6, 27125.	1.6	83
213	Rapid flow cytometric measurement of protein inclusions and nuclear trafficking. Scientific Reports, 2016, 6, 31138.	1.6	31
214	Highly potent intracellular membrane-associated AÎ² seeds. Scientific Reports, 2016, 6, 28125.	1.6	18
215	Extracellular Vesicles Isolated from the Brains of rTg4510 Mice Seed Tau Protein Aggregation in a Threshold-dependent Manner. Journal of Biological Chemistry, 2016, 291, 12445-12466.	1.6	208
216	The Priority position paper: Protecting Europe's food chain from prions. Prion, 2016, 10, 165-181.	0.9	13
217	Human-to-mouse prion-like propagation of mutant huntingtin protein. Acta Neuropathologica, 2016, 132, 577-592.	3.9	145
218	Darwin's Pangenesis as a molecular theory of inherited diseases. Gene, 2016, 582, 19-22.	1.0	6
219	Phase Separation: Linking Cellular Compartmentalization to Disease. Trends in Cell Biology, 2016, 26, 547-558.	3.6	291
220	Intracerebral Injection of Metal-Binding Domain of AÎ² Comprising the Isomerized Asp7 Increases the Amyloid Burden in Transgenic Mice. Neurotoxicity Research, 2016, 29, 551-557.	1.3	28
221	Reciprocal signals between microglia and neurons regulate Î±-synuclein secretion by exophagy through a neuronal cJUN-N-terminal kinase-signaling axis. Journal of Neuroinflammation, 2016, 13, 59.	3.1	20
222	sFRP-mediated Wnt sequestration as a potential therapeutic target for Alzheimerâ€™s disease. International Journal of Biochemistry and Cell Biology, 2016, 75, 104-111.	1.2	14

#	Article	IF	Citations
223	Conversion of Synthetic AÎ² toIn VivoActive Seeds and Amyloid Plaque Formation in a Hippocampal Slice Culture Model. Journal of Neuroscience, 2016, 36, 5084-5093.	1.7	41
224	Fracture and Growth Are Competing Forces Determining the Fate of Conformers in Tau Fibril Populations. Journal of Biological Chemistry, 2016, 291, 12271-12281.	1.6	30
225	Generation of Regionally Specific Neural Progenitor Cells (NPCs) and Neurons from Human Pluripotent Stem Cells (hPSCs). Methods in Molecular Biology, 2016, 1516, 121-144.	0.4	5
226	What amyloid ligands can tell us about molecular polymorphism and disease. Neurobiology of Aging, 2016, 42, 205-212.	1.5	11
227	UPS Activation in the Battle Against Aging and Aggregation-Related Diseases: An Extended Review. Methods in Molecular Biology, 2016, 1449, 1-70.	0.4	18
228	Molecular and Biological Compatibility with Host Alpha-Synuclein Influences Fibril Pathogenicity. Cell Reports, 2016, 16, 3373-3387.	2.9	141
229	Pathological Î±-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science, 2016, 353, .	6.0	521
230	Immune receptor for pathogenic Î±-synuclein. Science, 2016, 353, 1498-1499.	6.0	5
231	Novel Dimer Compounds That Bind Î±-Synuclein Can Rescue Cell Growth in a Yeast Model Overexpressing Î±-Synuclein. A Possible Prevention Strategy for Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2016, 7, 1671-1680.	1.7	11
232	Diagnosing Sporadic Creutzfeldt-Jakob Disease by the Detection of Abnormal Prion Protein in Patient Urine. JAMA Neurology, 2016, 73, 1454.	4.5	25
233	Can Creutzfeldt-Jakob disease unravel the mysteries of Alzheimer?. Prion, 2016, 10, 369-376.	0.9	6
234	Epilepsy, amyloid-Î², and D1 dopamine receptors: a possible pathogenetic link?. Neurobiology of Aging, 2016, 48, 161-171.	1.5	71
236	Real-time monitoring of amyloid growth in a rigid gel matrix. Analytical Biochemistry, 2016, 511, 13-16.	1.1	2
237	Anti-aging treatments slow propagation of synucleinopathy by restoring lysosomal function. Autophagy, 2016, 12, 1849-1863.	4.3	59
238	Amyloid-Î² containing isoaspartate 7 as potential biomarker and drug target in Alzheimer's disease. Mendeleev Communications, 2016, 26, 269-275.	0.6	33
239	Prionâ€like propagation as a pathogenic principle in frontotemporal dementia. Journal of Neurochemistry, 2016, 138, 163-183.	2.1	54
240	Interactions between heme and tau-derived R1 peptides: binding and oxidative reactivity. Dalton Transactions, 2016, 45, 14343-14351.	1.6	9
241	<scp>G</scp>ut <scp>F</scp>eelings <scp>Ab</scp>out Î±â€<scp>S</scp>ynuclein in <scp>G</scp>astrointestinal <scp>B</scp>iopsies: <scp>B</scp>iomarker in the <scp>M</scp>aking?. Movement Disorders, 2016, 31, 193-202.	2.2	56

#	Article	IF	Citations
242	Altered mRNP granule dynamics in FTLD pathogenesis. Journal of Neurochemistry, 2016, 138, 112-133.	2.1	63
243	Review: Sporadic Parkinson's disease: development and distribution of Î±â€synuclein pathology. Neuropathology and Applied Neurobiology, 2016, 42, 33-50.	1.8	309
244	Review: Spreading the word: precise animal models and validated methods are vital when evaluating prionâ€like behaviour of alphaâ€synuclein. Neuropathology and Applied Neurobiology, 2016, 42, 51-76.	1.8	65
245	Molecular pathogenesis of human amyloidosis: Lessons from Î²₂â€microglobulinâ€related amyloidosis. Pathology International, 2016, 66, 193-201.	0.6	35
246	Guinea Pig Prion Protein Supports Rapid Propagation of Bovine Spongiform Encephalopathy and Variant Creutzfeldt-Jakob Disease Prions. Journal of Virology, 2016, 90, 9558-9569.	1.5	3
247	Potential Pathways of Abnormal Tau and Î±-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases. Cold Spring Harbor Perspectives in Biology, 2016, 8, a023630.	2.3	101
248	Collinge et al. reply. Nature, 2016, 535, E2-E3.	13.7	3
250	Holdase activity of secreted Hsp70 masks amyloid-Î²42 neurotoxicity in Drosophila. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5212-21.	3.3	60
251	How neuroinflammation contributes to neurodegeneration. Science, 2016, 353, 777-783.	6.0	1,408
252	Copper-induced structural conversion templates prion protein oligomerization and neurotoxicity. Science Advances, 2016, 2, e1600014.	4.7	48
253	Cerebral vascular amyloid seeds drive amyloid Î²-protein fibril assembly with a distinct anti-parallel structure. Nature Communications, 2016, 7, 13527.	5.8	28
254	Amyloid-Î² transmission or unexamined bias?. Nature, 2016, 537, E7-E9.	13.7	4
255	Collinge et al. reply. Nature, 2016, 537, E9-E9.	13.7	1
256	Localizing Sources of Brain Disease Progression with Network Diffusion Model. IEEE Journal on Selected Topics in Signal Processing, 2016, 10, 1214-1225.	7.3	30
257	Ocular indicators of Alzheimerâ€™s: exploring disease in the retina. Acta Neuropathologica, 2016, 132, 767-787.	3.9	205
258	Catastrophic cliffs: a partial suggestion for selective vulnerability in neurodegenerative diseases. Biochemical Society Transactions, 2016, 44, 659-661.	1.6	12
259	Tau and tauopathies. Brain Research Bulletin, 2016, 126, 238-292.	1.4	444
260	More than Meets the Eye: Hidden Structures in the Proteome. Annual Review of Virology, 2016, 3, 373-386.	3.0	8

#	Article	IF	Citations
261	Seeds of neuroendocrine doubt. Nature, 2016, 535, E1-E2.	13.7	8
262	Copperâ€Aî² Peptides and Oxidation of Catecholic Substrates: Reactivity and Endogenous Peptide Damage. Chemistry - A European Journal, 2016, 22, 16964-16973.	1.7	18
263	Decoding ALS: from genes to mechanism. Nature, 2016, 539, 197-206.	13.7	1,533
264	The road to restoring neural circuits for the treatment of Alzheimer's disease. Nature, 2016, 539, 187-196.	13.7	426
265	Defects in trafficking bridge Parkinson's disease pathology and genetics. Nature, 2016, 539, 207-216.	13.7	373
266	Mammalian prions and their wider relevance in neurodegenerative diseases. Nature, 2016, 539, 217-226.	13.7	193
267	De novo design of a biologically active amyloid. Science, 2016, 354, .	6.0	63
268	Secretory pathway retention of mutant prion protein induces p38-MAPK activation and lethal disease in mice. Scientific Reports, 2016, 6, 24970.	1.6	22
269	Human cystatin C monomer, dimer, oligomer, and amyloid structures are related to health and disease. FEBS Letters, 2016, 590, 4192-4201.	1.3	21
270	Differences in vulnerability of neurons and astrocytes to heme oxygenase-1 modulation: Implications for mitochondrial ferritin. Scientific Reports, 2016, 6, 24200.	1.6	26
271	Time-dependent X-ray diffraction studies on urea/hen egg white lysozyme complexes reveal structural changes that indicate onset of denaturation. Scientific Reports, 2016, 6, 32277.	1.6	13
272	Identification of Anti-prion Compounds using a Novel Cellular Assay. Journal of Biological Chemistry, 2016, 291, 26164-26176.	1.6	23
273	Effect of Mutation on an Aggregation-Prone Segment of p53: From Monomer to Dimer to Multimer. Journal of Physical Chemistry B, 2016, 120, 11665-11673.	1.2	12
274	Interplay of histidine residues of the Alzheimerâ€™s disease Aî² peptide governs its Zn-induced oligomerization. Scientific Reports, 2016, 6, 21734.	1.6	81
275	A Decentralized Approach to the Formulation of Hypotheses: A Hierarchical Structural Model for a Prion Self-Assembled System. Scientific Reports, 2016, 6, 30633.	1.6	0
276	Î±-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. Trends in Neurosciences, 2016, 39, 750-762.	4.2	120
277	Vitro toxicity assessments of nano-ZnS on bovine serum albumin by multispectroscopic methods. Canadian Journal of Chemistry, 2016, 94, 877-881.	0.6	1
278	A Mathematical Model for the Proliferation, Accumulation and Spread of Pathogenic Proteins Along Neuronal Pathways with Locally Anomalous Trapping. Mathematical Modelling of Natural Phenomena, 2016, 11, 142-156.	0.9	4

#	Article	IF	Citations
279	Tunneling nanotube (TNT)-mediated neuron-to neuron transfer of pathological Tau protein assemblies. Acta Neuropathologica Communications, 2016, 4, 117.	2.4	207
280	Exposure to bacterial endotoxin generates a distinct strain of Î±-synuclein fibril. Scientific Reports, 2016, 6, 30891.	1.6	113
281	Binding, internalization and fate of <scp>H</scp>untingtin <scp>E</scp>xon1 fibrillar assemblies in mitotic and nonmitotic neuroblastoma cells. Neuropathology and Applied Neurobiology, 2016, 42, 137-152.	1.8	17
282	Metabolite amyloids: a new paradigm for inborn error of metabolism disorders. Journal of Inherited Metabolic Disease, 2016, 39, 483-488.	1.7	29
283	The Prion-Like Properties of Amyloid-Î² Assemblies: Implications for Alzheimer's Disease. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a024398.	2.9	71
284	Sequence-specific protein aggregation generates defined protein knockdowns in plants. Plant Physiology, 2016, 171, pp.00335.2016.	2.3	24
286	Ex vivo mammalian prions are formed of paired double helical prion protein fibrils. Open Biology, 2016, 6, 160035.	1.5	55
287	Molecular and genetic inflammation networks in major human diseases. Molecular BioSystems, 2016, 12, 2318-2341.	2.9	49
288	The HET-S/s Prion Motif in the Control of Programmed Cell Death. Cold Spring Harbor Perspectives in Biology, 2016, 8, a023515.	2.3	40
289	The Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimerâ€™s Disease. Molecular Neurobiology, 2016, 53, 905-931.	1.9	74
290	Updated TDP-43 in Alzheimerâ€™s disease staging scheme. Acta Neuropathologica, 2016, 131, 571-585.	3.9	244
291	Revisiting supersaturation as a factor determining amyloid fibrillation. Current Opinion in Structural Biology, 2016, 36, 32-39.	2.6	57
292	Distinct prion-like strains of amyloid beta implicated in phenotypic diversity of Alzheimer's disease. Prion, 2016, 10, 9-17.	0.9	57
293	An Enhanced Genetic Algorithm for <italic>Ab Initio</italic> Protein Structure Prediction. IEEE Transactions on Evolutionary Computation, 2016, 20, 627-644.	7.5	29
294	HSF Inhibits the Progression of Age-Related Neurodegenerative Diseases. , 2016, , 213-242.		0
295	Heat Shock Factor. , 2016, , .		14
296	Prion-like propagation of mutant SOD1 misfolding and motor neuron disease spread along neuroanatomical pathways. Acta Neuropathologica, 2016, 131, 103-114.	3.9	117
297	5-((3-Amidobenzyl)oxy)nicotinamides as Sirtuin 2 Inhibitors. Journal of Medicinal Chemistry, 2016, 59, 2928-2941.	2.9	26

#	Article	IF	Citations
298	Conformational Compatibility Is Essential for Heterologous Aggregation of Î±-Synuclein. ACS Chemical Neuroscience, 2016, 7, 719-727.	1.7	26
299	Nanoscopic insights into seeding mechanisms and toxicity of Î±-synuclein species in neurons. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3815-3819.	3.3	63
300	A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nature Reviews Neuroscience, 2016, 17, 251-260.	4.9	251
301	Structural studies on the mechanism of protein aggregation in age related neurodegenerative diseases. Mechanisms of Ageing and Development, 2016, 156, 1-13.	2.2	31
302	Conformational Dynamics of Specific AÎ² Oligomers Govern Their Ability To Replicate and Induce Neuronal Apoptosis. Biochemistry, 2016, 55, 2238-2250.	1.2	26
303	CSF biomarkers in neurodegenerative and vascular dementias. Progress in Neurobiology, 2016, 138-140, 36-53.	2.8	34
304	Anthropogenic pollutants may increase the incidence of neurodegenerative disease in an aging population. Toxicology, 2016, 341-343, 41-46.	2.0	22
305	Network-selective vulnerability of the human cerebellum to Alzheimerâ€™s disease and frontotemporal dementia. Brain, 2016, 139, 1527-1538.	3.7	168
306	Covalent Surface Modification of Prions: A Mass Spectrometry-Based Means of Detecting Distinctive Structural Features of Prion Strains. Biochemistry, 2016, 55, 894-902.	1.2	10
307	Computer-based magnetic resonance imaging as a tool in clinical diagnosis in neurodegenerative diseases. Expert Review of Neurotherapeutics, 2016, 16, 295-306.	1.4	20
308	Distinctive pathological mechanisms involved in primary progressiveÂaphasias. Neurobiology of Aging, 2016, 38, 82-92.	1.5	45
309	Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob Disease. JAMA Neurology, 2016, 73, 447.	4.5	41
310	Alzheimer's disease. Lancet, The, 2016, 388, 505-517.	6.3	2,430
311	Yeast and Fungal Prions. Advances in Genetics, 2016, 93, 191-236.	0.8	25
312	Proteolysis triggers self-assembly and unmasks innate immune function of a human Î±-defensin peptide. Chemical Science, 2016, 7, 1738-1752.	3.7	31
313	A low absolute number of expanded transcripts is involved in myotonic dystrophy type 1 manifestation in muscle. Human Molecular Genetics, 2016, 25, 1648-1662.	1.4	31
314	Heterotypic seeding of Tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of Tau-pathology in vivo. Acta Neuropathologica, 2016, 131, 549-569.	3.9	129
315	A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 570-579.	0.9	138

#	Article	IF	Citations
316	Magnetic resonance imaging as a potential biomarker for Parkinson's disease. Translational Research, 2016, 175, 4-16.	2.2	23
317	Zinc-induced heterodimer formation between metal-binding domains of intact and naturally modified amyloid-beta species: implication to amyloid seeding in Alzheimerâ€™s disease?. Journal of Biomolecular Structure and Dynamics, 2016, 34, 2317-2326.	2.0	28
318	The association between alterations of eye movement control and cerebral intrinsic functional connectivity in Parkinsonâ€™s disease. Brain Imaging and Behavior, 2016, 10, 79-91.	1.1	36
319	Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. Progress in Neurobiology, 2017, 155, 171-193.	2.8	137
320	Altered modular organization of intrinsic brain functional networks in patients with Parkinsonâ€™s disease. Brain Imaging and Behavior, 2017, 11, 430-443.	1.1	27
321	From eyeless to neurological diseases. Experimental Eye Research, 2017, 156, 5-9.	1.2	19
322	New protein deposition tracers in the pipeline. EJNMMI Radiopharmacy and Chemistry, 2017, 1, 11.	1.8	15
323	Disease-specific patterns of cortical and subcortical degeneration in a longitudinal study of Alzheimer's disease and behavioural-variant frontotemporal dementia. NeuroImage, 2017, 151, 72-80.	2.1	89
324	Strain-specific Fibril Propagation by an AÎ² Dodecamer. Scientific Reports, 2017, 7, 40787.	1.6	41
325	Temperature-Induced Misfolding in Prion Protein: Evidence of Multiple Partially Disordered States Stabilized by Non-Native Hydrogen Bonds. Biochemistry, 2017, 56, 833-844.	1.2	30
326	Antisense transcription of the myotonic dystrophy locus yields low-abundant RNAs with and without (CAG)n repeat. RNA Biology, 2017, 14, 1374-1388.	1.5	25
327	Synthesis and characterization of styryl-BODIPY derivatives for monitoring in vitro Tau aggregation. Sensors and Actuators B: Chemical, 2017, 244, 673-683.	4.0	39
328	Reversible aggregation of HIV-1 Gag proteins mediated by nucleic acids. Biochemical and Biophysical Research Communications, 2017, 482, 1437-1442.	1.0	3
329	Distinct Mechanisms Determine Î±-Synuclein Fibril Morphology during Growth and Maturation. ACS Chemical Neuroscience, 2017, 8, 538-547.	1.7	41
330	Active site-targeted carbon dots for the inhibition of human insulin fibrillation. Journal of Materials Chemistry B, 2017, 5, 2010-2018.	2.9	29
332	Parkinsonâ€™s disease as a multisystem disorder. Journal of Neural Transmission, 2017, 124, 709-713.	1.4	43
333	Sialylation Controls Prion Fate in Vivo. Journal of Biological Chemistry, 2017, 292, 2359-2368.	1.6	32
334	The gut microbiome in human neurological disease: A review. Annals of Neurology, 2017, 81, 369-382.	2.8	388

#	Article	IF	Citations
335	Amyloid A Amyloidosis. Veterinary Pathology, 2017, 54, 5-8.	0.8	7
336	Clearance of cerebral AÎ² in Alzheimerâ€™s disease: reassessing the role of microglia and monocytes. Cellular and Molecular Life Sciences, 2017, 74, 2167-2201.	2.4	199
337	Diagnostic pathology of Alzheimer's disease from routine microscopy to immunohistochemistry and experimental correlations. Annals of Diagnostic Pathology, 2017, 28, 24-29.	0.6	8
338	Design of multi-phase dynamic chemical networks. Nature Chemistry, 2017, 9, 799-804.	6.6	57
339	Propagation of pathological Î±-synuclein in marmoset brain. Acta Neuropathologica Communications, 2017, 5, 12.	2.4	142
340	Comparison of AT8 immunoreactivity in the locus ceruleus and hippocampus of 154 brains from routine autopsies. Neuropathology, 2017, 37, 306-310.	0.7	7
342	Neurodegenerative Disease Transmission and Transgenesis in Mice. Cold Spring Harbor Perspectives in Biology, 2017, 9, a023549.	2.3	12
343	Aberrant interhemispheric homotopic functional and structural connectivity in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 369.1-370.	0.9	38
344	Single cell imaging and quantification of TDP-43 and Î±-synuclein intercellular propagation. Scientific Reports, 2017, 7, 544.	1.6	16
345	Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathologica, 2017, 134, 187-205.	3.9	288
346	Transfer of pathogenic and nonpathogenic cytosolic proteins between spinal cord motor neurons in vivo in chimeric mice. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E3139-E3148.	3.3	18
347	The multitude of therapeutic targets in neurodegenerative proteinopathies. , 2017, , 1-20.		1
348	Preclinical models of Alzheimerâ€™s disease for identification and preclinical validation of therapeutic targets: from fine-tuning strategies for validated targets to new venues for therapy. , 2017, , 115-156.		2
349	Drosophila models of prionopathies: insight into prion protein function, transmission, and neurotoxicity. Current Opinion in Genetics and Development, 2017, 44, 141-148.	1.5	18
350	Cellular Osmolytes. , 2017, , .		5
351	<scp>TREM</scp>2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Reports, 2017, 18, 1186-1198.	2.0	240
352	Expression, purification, and characterization of recombinant 8ÂkDa gelsolin fragment. Protein Expression and Purification, 2017, 135, 33-36.	0.6	1
353	The Exceptional Vulnerability of Humans to Alzheimerâ€™s Disease. Trends in Molecular Medicine, 2017, 23, 534-545.	3.5	74

#	Article	IF	Citations
354	Prion-like mechanisms and potential therapeutic targets in neurodegenerative disorders. , 2017, 172, 22-33.		52
355	Taking a Bite Out of Amyloid: Mechanistic Insights into Î±-Synuclein Degradation by Cathepsin L. Biochemistry, 2017, 56, 3881-3884.	1.2	26
356	Selective imaging of internalized proteopathic Î±-synuclein seeds in primary neurons reveals mechanistic insight into transmission of synucleinopathies. Journal of Biological Chemistry, 2017, 292, 13482-13497.	1.6	131
357	Spreading of Pathology in Alzheimerâ€™s Disease. Neurotoxicity Research, 2017, 32, 707-722.	1.3	13
358	Modulation of Protein Aggregation/Fibrillation by Osmolytes. , 2017, , 121-142.		0
359	Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins. Acta Neuropathologica, 2017, 134, 629-653.	3.9	201
360	An ATRâ€“FTIR Sensor Unraveling the Drug Intervention of Methylene Blue, Congo Red, and Berberine on Human Tau and AÎ². ACS Medicinal Chemistry Letters, 2017, 8, 710-714.	1.3	12
361	Using bicistronic constructs to evaluate the chaperone activities of heat shock proteins in cells. Scientific Reports, 2017, 7, 2387.	1.6	5
362	p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis. Cell Death and Differentiation, 2017, 24, 1784-1798.	5.0	99
363	Different Molecular Mechanisms Mediate Direct or Glia-Dependent Prion Protein Fragment 90â€“231 Neurotoxic Effects in Cerebellar Granule Neurons. Neurotoxicity Research, 2017, 32, 381-397.	1.3	5
364	Imaging plus X: multimodal models of neurodegenerative disease. Current Opinion in Neurology, 2017, 30, 371-379.	1.8	75
365	Selective lowering of synapsins induced by oligomeric Î±-synuclein exacerbates memory deficits. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4648-E4657.	3.3	45
366	The Role of Microglia in the Etiology and Evolution of Chronic Traumatic Encephalopathy. Shock, 2017, 48, 276-283.	1.0	24
367	The gut-brain axis in Parkinson's disease: Possibilities for food-based therapies. European Journal of Pharmacology, 2017, 817, 86-95.	1.7	155
368	Reâ€imagining Alzheimer's disease â€“ the diminishing importance of amyloid and a glimpse of what lies ahead. Journal of Neurochemistry, 2017, 143, 432-444.	2.1	83
369	Model membrane size-dependent amyloidogenesis of Alzheimer's amyloid-Î² peptides. Physical Chemistry Chemical Physics, 2017, 19, 16257-16266.	1.3	42
370	Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex. JAMA Neurology, 2017, 74, 813.	4.5	61
371	NanoEHS beyond toxicity â€“ focusing on biocorona. Environmental Science: Nano, 2017, 4, 1433-1454.	2.2	43

#	Article	IF	Citations
372	Toward precision medicine: tailoring interventional strategies based on noninvasive brain stimulation for motor recovery after stroke. Current Opinion in Neurology, 2017, 30, 388-397.	1.8	51
373	Molecular mechanisms of chronic traumatic encephalopathy. Current Opinion in Biomedical Engineering, 2017, 1, 23-30.	1.8	15
374	The underlying mechanism of prodromal PD: insights from the parasympathetic nervous system and the olfactory system. Translational Neurodegeneration, 2017, 6, 4.	3.6	19
375	Amplification of distinct Î±-synuclein fibril conformers through protein misfolding cyclic amplification. Experimental and Molecular Medicine, 2017, 49, e314-e314.	3.2	39
376	Novel conformationâ€selective alphaâ€synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease. Neuropathology and Applied Neurobiology, 2017, 43, 604-620.	1.8	51
377	Neuropathological Staging of Brain Pathology in Sporadic Parkinsonâ€™s disease: Separating the Wheat from the Chaff. Journal of Parkinson's Disease, 2017, 7, S71-S85.	1.5	252
378	Roles of tau protein in health and disease. Acta Neuropathologica, 2017, 133, 665-704.	3.9	639
379	Amyloid-Î² accumulation in the CNS in human growth hormone recipients in the UK. Acta Neuropathologica, 2017, 134, 221-240.	3.9	85
380	New insights into mechanisms of small vessel disease stroke from genetics. Clinical Science, 2017, 131, 515-531.	1.8	50
381	Exosomes and Microvesicles. Methods in Molecular Biology, 2017, , .	0.4	10
382	Rationally Designed Peptides and Peptidomimetics as Inhibitors of Amyloid-Î² (AÎ²) Aggregation: Potential Therapeutics of Alzheimerâ€™s Disease. ACS Combinatorial Science, 2017, 19, 55-80.	3.8	168
383	Isolation of Exosomes and Microvesicles from Cell Culture Systems to Study Prion Transmission. Methods in Molecular Biology, 2017, 1545, 153-176.	0.4	25
384	Structural Characteristics of Î±-Synuclein Oligomers. International Review of Cell and Molecular Biology, 2017, 329, 79-143.	1.6	95
385	Prion-like Protein Seeding and the Pathobiology of Alzheimerâ€™s Disease. , 2017, , 57-82.		0
386	Improving Biopharmaceutical Safety through Verification-Based Quality Control. Trends in Biotechnology, 2017, 35, 1140-1155.	4.9	14
387	Biophysical Aspects of Alzheimerâ€™s Disease: Implications for Pharmaceutical Sciences. Pharmaceutical Research, 2017, 34, 2628-2636.	1.7	1
388	The molecular basis of Alzheimer's plaques. Science, 2017, 358, 45-46.	6.0	24
389	Tau-based therapies in neurodegeneration: opportunities and challenges. Nature Reviews Drug Discovery, 2017, 16, 863-883.	21.5	193

#	Article	IF	Citations
390	Mitochondrial ROS-mediated post-transcriptional regulation of Î±-synuclein through miR-7 and miR-153. Neuroscience Letters, 2017, 661, 132-136.	1.0	38
391	Exploring the Aggregation Mechanism of Intrinsically Disordered Tau Protein. World Scientific Lecture and Course Notes in Chemistry, 2017, , 51-71.	0.2	1
392	Deciphering neurodegeneration. Neurology, 2017, 89, 1758-1759.	1.5	17
393	Applications of the real-time quaking-induced conversion assay in diagnosis, prion strain-typing, drug pre-screening and other amyloidopathies. Expert Review of Molecular Diagnostics, 2017, 17, 897-904.	1.5	16
394	Amyloidogenesis of Tau protein. Protein Science, 2017, 26, 2126-2150.	3.1	102
395	Differential HspBP1 expression accounts for the greater vulnerability of neurons than astrocytes to misfolded proteins. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E7803-E7811.	3.3	37
396	What's next for genomics and prion diseases?. Future Science OA, 2017, 3, FSO188.	0.9	1
397	Microbiota and neurodegenerative diseases. Current Opinion in Neurology, 2017, 30, 630-638.	1.8	64
398	The tyrosine phosphatase PTPN13/FAP-1 links calpain-2, TBI and tau tyrosine phosphorylation. Scientific Reports, 2017, 7, 11771.	1.6	22
399	Seed-induced acceleration of amyloid-Î² mediated neurotoxicity in vivo. Nature Communications, 2017, 8, 512.	5.8	57
400	A component analysis of the free energies of folding of 35 proteins: A consensus view on the thermodynamics of folding at the molecular level. Journal of Computational Chemistry, 2017, 38, 2791-2801.	1.5	14
401	Prion Protein and Genetic Susceptibility to Diseases Caused by Its Misfolding. Progress in Molecular Biology and Translational Science, 2017, 150, 123-145.	0.9	2
402	Fibril structure of amyloid-Î²(1â€“42) by cryoâ€“electron microscopy. Science, 2017, 358, 116-119.	6.0	801
403	Induction of IAPP amyloid deposition and associated diabetic abnormalities by a prion-like mechanism. Journal of Experimental Medicine, 2017, 214, 2591-2610.	4.2	72
404	Protein astrogliopathies in human neurodegenerative diseases and aging. Brain Pathology, 2017, 27, 675-690.	2.1	68
405	APP/AÎ² structural diversity and Alzheimer's disease pathogenesis. Neurochemistry International, 2017, 110, 1-13.	1.9	78
406	Mutant Huntingtin Is Secreted via a Late Endosomal/Lysosomal Unconventional Secretory Pathway. Journal of Neuroscience, 2017, 37, 9000-9012.	1.7	64
407	<scp>APP</scp> mouse models for Alzheimer's disease preclinical studies. EMBO Journal, 2017, 36, 2473-2487.	3.5	530

#	Article	IF	Citations
408	Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 13018-13023.	3.3	170
409	The Biology and Pathobiology of Î±-Synuclein. , 2017, , 109-130.		1
410	Toward a Soluble Model System for the Amyloid State. Journal of the American Chemical Society, 2017, 139, 16434-16437.	6.6	4
411	Tau deletion promotes brain insulin resistance. Journal of Experimental Medicine, 2017, 214, 2257-2269.	4.2	158
412	Nanoscale clustering of the neurotrophin receptor TrkB revealed by super-resolution STED microscopy. Nanoscale, 2017, 9, 9797-9804.	2.8	22
413	AÎ² seeding potency peaks in the early stages of cerebral Î²â€amyloidosis. EMBO Reports, 2017, 18, 1536-1544.	2.0	38
414	A clinicopathological approach to the diagnosis of dementia. Nature Reviews Neurology, 2017, 13, 457-476.	4.9	233
415	Physico-Pathologic Mechanisms Involved in Neurodegeneration: Misfolded Protein-Plasma Membrane Interactions. Neuron, 2017, 95, 33-50.	3.8	83
416	Ovine recombinant PrP as an inhibitor of ruminant prion propagation in vitro. Prion, 2017, 11, 265-276.	0.9	1
417	Fibrilâ€“Barrel Transitions in Cylindrin Amyloids. Journal of Chemical Theory and Computation, 2017, 13, 3936-3944.	2.3	28
418	Transmission of pathogenic protein aggregates in Alzheimerâ€™s disease. Molecular Biology, 2017, 51, 368-371.	0.4	8
419	Glial contributions to neurodegeneration in tauopathies. Molecular Neurodegeneration, 2017, 12, 50.	4.4	283
420	Endoplasmic reticulum stress and inflammation in the central nervous system. Molecular Neurodegeneration, 2017, 12, 42.	4.4	196
421	AÎ² seeds and prions: How close the fit?. Prion, 2017, 11, 215-225.	0.9	29
422	Amyotrophic lateral sclerosis with frontotemporal dementia (ALS-FTD) syndrome as a phenotype of Creutzfeldt-Jakob disease (CJD)? A case report. Journal of the Neurological Sciences, 2017, 372, 444-446.	0.3	12
423	Danger-associated molecular patterns in Alzheimerâ€™s disease. Journal of Leukocyte Biology, 2017, 101, 87-98.	1.5	158
424	Cortical Manifestations in Amyotrophic Lateral Sclerosis. , 2017, , 223-242.		1
425	Identification of novel fluorescent probes preventing PrP Sc replication in prion diseases. European Journal of Medicinal Chemistry, 2017, 127, 859-873.	2.6	39

#	Article	IF	Citations
426	Amyloid-beta and tau pathology following repetitive mild traumatic brain injury. Biochemical and Biophysical Research Communications, 2017, 483, 1137-1142.	1.0	78
427	Inhomogeneous distribution of <scp>A</scp>lzheimer pathology along the isocortical relief. Are cortical convolutions an <scp>A</scp>chilles heel of evolution?. Brain Pathology, 2017, 27, 603-611.	2.1	21
428	Neurodegeneration and <scp>RNA</scp>â€binding proteins. Wiley Interdisciplinary Reviews RNA, 2017, 8, e1394.	3.2	33
429	Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. Progress in Biophysics and Molecular Biology, 2017, 123, 16-41.	1.4	64
430	Targeting chaperones, heat shock factor-1, and unfolded protein response: Promising therapeutic approaches for neurodegenerative disorders. Ageing Research Reviews, 2017, 35, 155-175.	5.0	37
431	Progression of alphaâ€synuclein pathology in multiple system atrophy of the cerebellar type. Neuropathology and Applied Neurobiology, 2017, 43, 315-329.	1.8	44
432	Prion-Like Polymerization in Immunity and Inflammation. Cold Spring Harbor Perspectives in Biology, 2017, 9, a023580.	2.3	44
433	Microglia-derived ASC specks cross-seed amyloid-Î² in Alzheimerâ€™s disease. Nature, 2017, 552, 355-361.	13.7	664
434	Medicinal Chemistry of Hybrids for Neurodegenerative Diseases. , 2017, , 259-277.		4
435	Distinct influence of specific versus global connectivity on the different Alzheimerâ€™s disease biomarkers. Brain, 2017, 140, 3317-3328.	3.7	60
436	Vertebrate food products as a potential source of prion-like Î±-synuclein. Npj Parkinson's Disease, 2017, 3, 33.	2.5	21
437	A hybrid model to predict proteins tertiary structure. , 2017, , .		3
438	Diaschisis-Like Association of Hippocampal Atrophy and Posterior Cingulate Cortex Hypometabolism in Cognitively Normal Elderly Depends on Impaired Integrity of Parahippocampal Cingulum Fibers. Journal of Alzheimer's Disease, 2017, 60, 1285-1294.	1.2	3
439	New Insight into Alzheimerâ€™s Disease via Caspase 3-cleaved Tau: Pathogenic Role in Tau Oligomer Formation and Memory Deficits. , 2017, 07, .		0
440	Reduced Abundance and Subverted Functions of Proteins in Prion-Like Diseases: Gained Functions Fascinate but Lost Functions Affect Aetiology. International Journal of Molecular Sciences, 2017, 18, 2223.	1.8	9
441	Exosomes, an Unmasked Culprit in Neurodegenerative Diseases. Frontiers in Neuroscience, 2017, 11, 26.	1.4	110
442	Prelysosomal Compartments in the Unconventional Secretion of Amyloidogenic Seeds. International Journal of Molecular Sciences, 2017, 18, 227.	1.8	24
443	Unraveling Prion Protein Interactions with Aptamers and Other PrP-Binding Nucleic Acids. International Journal of Molecular Sciences, 2017, 18, 1023.	1.8	40

#	Article	IF	Citations
444	Peptidylarginine Deiminasesâ€"Roles in Cancer and Neurodegeneration and Possible Avenues for Therapeutic Intervention via Modulation of Exosome and Microvesicle (EMV) Release?. International Journal of Molecular Sciences, 2017, 18, 1196.	1.8	70
445	Age-Dependent Protein Aggregation Initiates Amyloid-Î² Aggregation. Frontiers in Aging Neuroscience, 2017, 9, 138.	1.7	46
446	Perspective Insights into Disease Progression, Diagnostics, and Therapeutic Approaches in Alzheimer's Disease: A Judicious Update. Frontiers in Aging Neuroscience, 2017, 9, 356.	1.7	49
447	Differential Effects of Parkinsonâ€™s Disease on Interneuron Subtypes within the Human Anterior Olfactory Nucleus. Frontiers in Neuroanatomy, 2017, 11, 113.	0.9	19
448	A Shift from a Pivotal to Supporting Role for the Growth-Associated Protein (GAP-43) in the Coordination of Axonal Structural and Functional Plasticity. Frontiers in Cellular Neuroscience, 2017, 11, 266.	1.8	117
449	Exploring Braakâ€™s Hypothesis of Parkinsonâ€™s Disease. Frontiers in Neurology, 2017, 8, 37.	1.1	210
450	Functional Connectivity Mapping in the Animal Model: Principles and Applications of Resting-State fMRI. Frontiers in Neurology, 2017, 8, 200.	1.1	78
451	Analysis of Amyloid-Î² Pathology Spread in Mouse Models Suggests Spread Is Driven by Spatial Proximity, Not Connectivity. Frontiers in Neurology, 2017, 8, 653.	1.1	20
452	Predictive Model of Spread of Progressive Supranuclear Palsy Using Directional Network Diffusion. Frontiers in Neurology, 2017, 8, 692.	1.1	36
453	Longitudinal Diffusion Tensor Imaging-Based Assessment of Tract Alterations: An Application to Amyotrophic Lateral Sclerosis. Frontiers in Human Neuroscience, 2017, 11, 567.	1.0	26
454	Metallothionein, Copper and Alpha-Synuclein in Alpha-Synucleinopathies. Frontiers in Neuroscience, 2017, 11, 114.	1.4	52
455	The Evidence for the Spread and Seeding Capacities of the Mutant Huntingtin Protein in in Vitro Systems and Their Therapeutic Implications. Frontiers in Neuroscience, 2017, 11, 647.	1.4	33
456	Creutzfeldt-Jakob disease: recent developments. F1000Research, 2017, 6, 2053.	0.8	71
457	Connectivity, not region-intrinsic properties, predicts regional vulnerability to progressive tau pathology in mouse models of disease. Acta Neuropathologica Communications, 2017, 5, 61.	2.4	26
458	Are exosomes the vehicle for protein aggregate propagation in neurodegenerative diseases?. Acta Neuropathologica Communications, 2017, 5, 64.	2.4	56
459	Cell model for the identification and characterization of prion-like components from Alzheimer brain tissue. Biochemical and Biophysical Research Communications, 2018, 497, 857-862.	1.0	0
460	Amyloid-Î² with isomerized Asp7 cytotoxicity is coupled to protein phosphorylation. Scientific Reports, 2018, 8, 3518.	1.6	24
461	A method for inferring regional origins of neurodegeneration. Brain, 2018, 141, 863-876.	3.7	37

#	Article	IF	Citations
462	Mechanism of aggregation and membrane interactions of mammalian prion protein. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 1927-1935.	1.4	37
463	Amyloidâ€Like Fibrillary Morphology Originated by Tyrosineâ€Containing Aromatic Hexapeptides. Chemistry - A European Journal, 2018, 24, 6804-6817.	1.7	28
464	Differential Î±-synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity. Acta Neuropathologica, 2018, 135, 855-875.	3.9	94
465	Amyloid assembly and disassembly. Journal of Cell Science, 2018, 131, .	1.2	138
466	Novel Lipidized Analog of Prolactin-Releasing Peptide Improves Memory Impairment and Attenuates Hyperphosphorylation of Tau Protein in a Mouse Model of Tauopathy. Journal of Alzheimer's Disease, 2018, 62, 1725-1736.	1.2	15
467	AGGRESCAN3D: Toward the Prediction of the Aggregation Propensities of Protein Structures. Methods in Molecular Biology, 2018, 1762, 427-443.	0.4	14
468	Amyloid blood biomarker detects Alzheimer's disease. EMBO Molecular Medicine, 2018, 10, .	3.3	145
469	Preserved Structural Network Organization Mediates Pathology Spread in Alzheimerâ€™s Disease Spectrum Despite Loss of White Matter Tract Integrity. Journal of Alzheimer's Disease, 2018, 65, 747-764.	1.2	21
470	Mutations in LRRK2 amplify cell-to-cell protein aggregate propagation: a hypothesis. Acta Neuropathologica, 2018, 135, 973-976.	3.9	4
471	Unravelling the inhibitory activity of Chlamydomonas reinhardtii sulfated polysaccharides against Î±-Synuclein fibrillation. Scientific Reports, 2018, 8, 5692.	1.6	14
472	Molecular subtypes of Alzheimerâ€™s disease. Scientific Reports, 2018, 8, 3269.	1.6	68
473	Osmotic stress induced toxicity exacerbates Parkinson's associated effects via dysregulation of autophagy in transgenic C. elegans model. Cellular Signalling, 2018, 45, 71-80.	1.7	8
474	Mass and charge distributions of amyloid fibers involved in neurodegenerative diseases: mapping heterogeneity and polymorphism. Chemical Science, 2018, 9, 2791-2796.	3.7	26
475	Recent insights into the cellular and molecular determinants of aging. Journal of Cell Science, 2018, 131, .	1.2	21
476	Amyloids of multiple species: are they helpful in survival?. Biological Reviews, 2018, 93, 1363-1386.	4.7	11
477	Anti-Prion Systems in Yeast and Inositol Polyphosphates. Biochemistry, 2018, 57, 1285-1292.	1.2	21
478	Concussion, microvascular injury, and early tauopathy in young athletes after impact head injury and an impact concussion mouse model. Brain, 2018, 141, 422-458.	3.7	315
479	Connectivity-based characterisation of subcortical grey matter pathology in frontotemporal dementia and ALS: a multimodal neuroimaging study. Brain Imaging and Behavior, 2018, 12, 1696-1707.	1.1	89

#	Article	IF	Citations
480	Out-of-Register AÎ²₄₂ Assemblies as Models for Neurotoxic Oligomers and Fibrils. Journal of Chemical Theory and Computation, 2018, 14, 1099-1110.	2.3	22
481	N-domain of angiotensin-converting enzyme hydrolyzes human and rat amyloid-Î²(1-16) peptides as arginine specific endopeptidase potentially enhancing risk of Alzheimerâ€™s disease. Scientific Reports, 2018, 8, 298.	1.6	12
482	Trial of Solanezumab for Mild Dementia Due to Alzheimerâ€™s Disease. New England Journal of Medicine, 2018, 378, 321-330.	13.9	795
483	Aging African green monkeys manifest transcriptional, pathological, and cognitive hallmarks of human Alzheimer's disease. Neurobiology of Aging, 2018, 64, 92-106.	1.5	37
484	The release and transmission of amyloid precursor protein via exosomes. Neurochemistry International, 2018, 114, 18-25.	1.9	13
485	Editorial: Pathogenic templating proteins in Neurodegenerative Disease. Neurobiology of Disease, 2018, 109, 175-177.	2.1	2
486	Salt-induced formations of partially folded intermediates and amyloid fibrils suggests a common underlying mechanism. Biophysical Reviews, 2018, 10, 493-502.	1.5	37
487	Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies. Journal of Biological Chemistry, 2018, 293, 2408-2421.	1.6	103
488	Astroglial and microglial contributions to iron metabolism disturbance in Parkinson's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 967-973.	1.8	41
489	Alzheimerâ€™s Disease: From Firing Instability to Homeostasis Network Collapse. Neuron, 2018, 97, 32-58.	3.8	188
490	The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases. Journal of Neuropathology and Experimental Neurology, 2018, 77, 2-20.	0.9	77
491	Detection of Creutzfeldt-Jakob disease prions in skin: implications for healthcare. Genome Medicine, 2018, 10, 22.	3.6	1
492	Autophagy and lysosomal pathways in nervous system disorders. Molecular and Cellular Neurosciences, 2018, 91, 167-208.	1.0	22
493	Structural insights from lipid-bilayer nanodiscs link Î±-Synuclein membrane-binding modes to amyloid fibril formation. Communications Biology, 2018, 1, 44.	2.0	79
494	Prion-like propagation of Î²-amyloid aggregates in the absence of APP overexpression. Acta Neuropathologica Communications, 2018, 6, 26.	2.4	41
495	Impact of membrane curvature on amyloid aggregation. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 1741-1764.	1.4	88
496	Amyloidosis-inducing activity of blood cells in mouse AApoAII amyloidosis. Experimental Animals, 2018, 67, 105-115.	0.7	3
497	Distinct thermodynamic signatures of oligomer generation in the aggregation of the amyloid-Î² peptide. Nature Chemistry, 2018, 10, 523-531.	6.6	129

#	Article	IF	Citations
498	Monitoring Cell-to-cell Transmission of Prion-like Protein Aggregates in Drosophila Melanogaster. Journal of Visualized Experiments, 2018, , .	0.2	3
499	Alzheimerâ€™s Disease, Oligomers, and Inflammation. Journal of Alzheimer's Disease, 2018, 62, 1261-1276.	1.2	141
500	Metabolic Dysfunction in Alzheimerâ€™s Disease: From Basic Neurobiology to Clinical Approaches. Journal of Alzheimer's Disease, 2018, 64, S405-S426.	1.2	66
501	Cause and consequence of AÎ² â€“ Lipid interactions in Alzheimer disease pathogenesis. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 1652-1662.	1.4	42
502	Prion-like Spreading in Tauopathies. Biological Psychiatry, 2018, 83, 337-346.	0.7	70
503	Chronic Traumatic Encephalopathy: Is Latency in Symptom Onset Explained by Tau Propagation?. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a024059.	2.9	28
504	AÎ² propagation and strains: Implications for the phenotypic diversity in Alzheimer's disease. Neurobiology of Disease, 2018, 109, 191-200.	2.1	57
505	Treatment with a non-toxic, self-replicating anti-prion delays or prevents prion disease in vivo. Molecular Psychiatry, 2018, 23, 777-788.	4.1	17
506	Î²-Amyloid Precursor Protein Intracellular Domain Controls Mitochondrial Function by Modulating Phosphatase and Tensin Homologâ€“Induced Kinase 1 Transcription in Cells and in Alzheimer Mice Models. Biological Psychiatry, 2018, 83, 416-427.	0.7	45
507	AÎ² truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 208-225.	1.8	53
508	The contribution of biophysical and structural studies of protein self-assembly to the design of therapeutic strategies for amyloid diseases. Neurobiology of Disease, 2018, 109, 178-190.	2.1	62
509	Critical appraisal of pathology transmission in the Î±-synuclein fibril model of Lewy body disorders. Experimental Neurology, 2018, 299, 172-196.	2.0	33
510	Blood-derived amyloid-Î² protein induces Alzheimerâ€™s disease pathologies. Molecular Psychiatry, 2018, 23, 1948-1956.	4.1	171
511	Amyloid precursor protein products concentrate in a subset of exosomes specifically endocytosed by neurons. Cellular and Molecular Life Sciences, 2018, 75, 757-773.	2.4	113
512	Do amyloid structures formed by Staphylococcus aureus phenol-soluble modulins have a biological function?. International Journal of Medical Microbiology, 2018, 308, 675-682.	1.5	52
513	Alzheimer's disease. European Journal of Neurology, 2018, 25, 59-70.	1.7	1,624
514	Aromaticâ€Turmerone Attenuates LPSâ€Induced Neuroinflammation and Consequent Memory Impairment by Targeting TLR4â€Dependent Signaling Pathway. Molecular Nutrition and Food Research, 2018, 62, 1700281.	1.5	29
515	A mechanistic insight into protein-ligand interaction, folding, misfolding, aggregation and inhibition of protein aggregates: An overview. International Journal of Biological Macromolecules, 2018, 106, 1115-1129.	3.6	43

#	Article	IF	Citations
516	Calpain-2 as a therapeutic target for acute neuronal injury. Expert Opinion on Therapeutic Targets, 2018, 22, 19-29.	1.5	28
517	Targeting the 26S Proteasome To Protect Against Proteotoxic Diseases. Trends in Molecular Medicine, 2018, 24, 18-29.	3.5	39
518	Deficits in synaptic function occur at medial perforant path-dentate granule cell synapses prior to Schaffer collateral-CA1 pyramidal cell synapses in the novel TgF344-Alzheimer's Disease Rat Model. Neurobiology of Disease, 2018, 110, 166-179.	2.1	45
519	Imaging the pathoanatomy of amyotrophic lateral sclerosis in vivo: targeting a propagation-based biological marker. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 374-381.	0.9	74
520	Order and disorder in the physiological membrane binding of Î±-synuclein. Current Opinion in Structural Biology, 2018, 48, 49-57.	2.6	60
521	Intracellular production of hydrogels and syntheticÂRNA granules by multivalent molecularÂinteractions. Nature Materials, 2018, 17, 79-89.	13.3	106
522	Protein-Based Inheritance: Epigenetics beyond the Chromosome. Molecular Cell, 2018, 69, 195-202.	4.5	138
523	Glucose metabolic brain patterns to discriminate amyotrophic lateral sclerosis from Parkinson plus syndromes. EJNMMI Research, 2018, 8, 110.	1.1	7
524	Brain structural alterations are distributed following functional, anatomic and genetic connectivity. Brain, 2018, 141, 3211-3232.	3.7	61
525	Sensing Î±â€synuclein From the Outside via the Prion Protein: Implications for Neurodegeneration. Movement Disorders, 2018, 33, 1675-1684.	2.2	19
526	Physiological and pathological functions of LRRK2: implications from substrate proteins. Neuronal Signaling, 2018, 2, NS20180005.	1.7	15
527	Prion Diseases. Neurologic Clinics, 2018, 36, 865-897.	0.8	44
528	Cyclic undecapeptide Cyclosporin A mediated inhibition of amyloid synthesis: Implications in alleviation of amyloid induced neurotoxicity. Scientific Reports, 2018, 8, 17283.	1.6	5
529	Transmission of amyloid-Î² protein pathology from cadaveric pituitary growth hormone. Nature, 2018, 564, 415-419.	13.7	122
530	A near atomic-scale view at the composition of amyloid-beta fibrils by atom probe tomography. Scientific Reports, 2018, 8, 17615.	1.6	20
531	Current state of Alzheimerâ€™s fluid biomarkers. Acta Neuropathologica, 2018, 136, 821-853.	3.9	370
533	Mechanistic and Structural Origins of the Asymmetric Barrier to Prion-like Cross-Seeding between Tau-3R and Tau-4R. Journal of Molecular Biology, 2018, 430, 5304-5312.	2.0	18
534	Selective vulnerability in neurodegenerative diseases. Nature Neuroscience, 2018, 21, 1350-1358.	7.1	384

#	Article	IF	Citations
535	Converging pathways in neurodegeneration, from genetics to mechanisms. Nature Neuroscience, 2018, 21, 1300-1309.	7.1	325
536	Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nature Neuroscience, 2018, 21, 1341-1349.	7.1	289
537	Perrault syndrome type 3 caused by diverse molecular defects in CLPP. Scientific Reports, 2018, 8, 12862.	1.6	27
538	The Early Events That Initiate Î²-Amyloid Aggregation in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 359.	1.7	85
539	Questions concerning the role of amyloid-Î² in the definition, aetiology and diagnosis of Alzheimerâ€™s disease. Acta Neuropathologica, 2018, 136, 663-689.	3.9	151
540	Multiphysics of Prionlike Diseases: Progression and Atrophy. Physical Review Letters, 2018, 121, 158101.	2.9	83
541	Determination of Parameters of Oxidative Stress in vitro Models of Neurodegenerative Diseases-A Review. Current Clinical Pharmacology, 2018, 13, 100-109.	0.2	19
542	Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nature Communications, 2018, 9, 4220.	5.8	176
543	N-Acetyl Cysteine Supplement Minimize Tau Expression and Neuronal Loss in Animal Model of Alzheimerâ€™s Disease. Brain Sciences, 2018, 8, 185.	1.1	17
544	Cytokines as Mediators of Neuroinflammation in Experimental Autoimmune Encephalomyelitis. Biochemistry (Moscow), 2018, 83, 1089-1103.	0.7	9
545	MRI-Based Mapping of Cerebral Propagation in Amyotrophic Lateral Sclerosis. Frontiers in Neuroscience, 2018, 12, 655.	1.4	13
546	Investigation of the quantitative accuracy of low-dose amyloid and tau PET imaging. Radiological Physics and Technology, 2018, 11, 451-459.	1.0	1
547	Polyion Complex Micelles for Protein Delivery. Australian Journal of Chemistry, 2018, 71, 768.	0.5	37
548	mHTT Seeding Activity: A Marker of Disease Progression and Neurotoxicity in Models of Huntingtonâ€™s Disease. Molecular Cell, 2018, 71, 675-688.e6.	4.5	50
549	A standard model of Alzheimerâ€™s disease?. Prion, 2018, 12, 261-265.	0.9	20
550	Anti-amyloid Therapy of Alzheimerâ€™s Disease: Current State and Prospects. Biochemistry (Moscow), 2018, 83, 1057-1067.	0.7	29
551	Prions activate a p38 MAPK synaptotoxic signaling pathway. PLoS Pathogens, 2018, 14, e1007283.	2.1	48
552	Alpha-synuclein and the prion hypothesis in Parkinson's disease. Revue Neurologique, 2018, 174, 644-652.	0.6	26

#	Article	IF	Citations
553	Converging Patterns of Î±-Synuclein Pathology in Multiple System Atrophy. Journal of Neuropathology and Experimental Neurology, 2018, 77, 1005-1016.	0.9	26
554	Assembly modes of hexaphenylalanine variants as function of the charge states of their terminal ends. Soft Matter, 2018, 14, 8219-8230.	1.2	18
555	Evolutionary biology and the risk of scrapie disease in sheep. Open Veterinary Journal, 2018, 8, 282.	0.3	2
556	Phosphorylation of the Amyloid-Beta Peptide Inhibits Zinc-Dependent Aggregation, Prevents Na,K-ATPase Inhibition, and Reduces Cerebral Plaque Deposition. Frontiers in Molecular Neuroscience, 2018, 11, 302.	1.4	33
557	Unconventional Secretion Mediates the Trans-cellular Spreading of Tau. Cell Reports, 2018, 23, 2039-2055.	2.9	194
558	Current and future circulating biomarkers for cardiac amyloidosis. Acta Pharmacologica Sinica, 2018, 39, 1133-1141.	2.8	10
559	A Filter Retardation Assay Facilitates the Detection and Quantification of Heat-Stable, Amyloidogenic Mutant Huntingtin Aggregates in Complex Biosamples. Methods in Molecular Biology, 2018, 1780, 31-40.	0.4	5
560	Cellular mechanisms responsible for cell-to-cell spreading of prions. Cellular and Molecular Life Sciences, 2018, 75, 2557-2574.	2.4	24
561	Ensemble cryoEM elucidates the mechanism of insulin capture and degradation by human insulin degrading enzyme. ELife, 2018, 7, .	2.8	45
562	Mechanisms of protein toxicity in neurodegenerative diseases. Cellular and Molecular Life Sciences, 2018, 75, 3159-3180.	2.4	103
563	Decreased alpha2 connectivity in EEG is correlated with the cognitive and psychiatric manifestations of Parkinsonâ€™s disease. Clinical Neurophysiology, 2018, 129, 1712-1713.	0.7	0
564	A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry. Journal of Neurochemistry, 2018, 146, 631-641.	2.1	17
565	Amyloid fibril structure of Î±-synuclein determined by cryo-electron microscopy. Cell Research, 2018, 28, 897-903.	5.7	339
566	Models of Network Spread and Network Degeneration in Brain Disorders. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 788-797.	1.1	37
567	The effect of truncation on prion-like properties of Î±-synuclein. Journal of Biological Chemistry, 2018, 293, 13910-13920.	1.6	63
568	Exosomes as possible spread factor and potential biomarkers in Alzheimer's disease: current concepts. Biomarkers in Medicine, 2018, 12, 1025-1033.	0.6	15
569	Disruption of Inferior Longitudinal Fasciculus Microstructure in Parkinson's Disease: A Systematic Review of Diffusion Tensor Imaging Studies. Frontiers in Neurology, 2018, 9, 598.	1.1	23
570	Shear-Induced Amyloid Formation in the Brain: III. The Roles of Shear Energy and Seeding in a Proposed Shear Model. Journal of Alzheimer's Disease, 2018, 65, 47-70.	1.2	14

#	Article	IF	Citations
571	Î±-Synuclein Aggregated with Tau and Î²-Amyloid in Human Platelets from Healthy Subjects: Correlation with Physical Exercise. Frontiers in Aging Neuroscience, 2018, 10, 17.	1.7	18
572	Longitudinal Diffusion Tensor Imaging Resembles Patterns of Pathology Progression in Behavioral Variant Frontotemporal Dementia (bvFTD). Frontiers in Aging Neuroscience, 2018, 10, 47.	1.7	13
573	Mathematical Modeling of Protein Misfolding Mechanisms in Neurological Diseases: A Historical Overview. Frontiers in Neurology, 2018, 9, 37.	1.1	43
574	Hemoglobin mRNA Changes in the Frontal Cortex of Patients with Neurodegenerative Diseases. Frontiers in Neuroscience, 2018, 12, 8.	1.4	26
575	Mechanisms of Î±-Synuclein Induced Synaptopathy in Parkinson's Disease. Frontiers in Neuroscience, 2018, 12, 80.	1.4	255
576	Pancreatic cancer foiled by a switch of tumour subtype. Nature, 2018, 557, 500-501.	13.7	8
577	A Study of Amyloid-Î² and Phosphotau in Plaques and Neurons in the Hippocampus of Alzheimerâ€™s Disease Patients. Journal of Alzheimer's Disease, 2018, 64, 417-435.	1.2	54
578	Detection of Aggregation-Competent Tau in Neuron-Derived Extracellular Vesicles. International Journal of Molecular Sciences, 2018, 19, 663.	1.8	140
579	The Structure of PrPSc Prions. Pathogens, 2018, 7, 20.	1.2	71
580	Sabotage by the brainâ€™s supporting cells helps fuel neurodegeneration. Nature, 2018, 557, 499-500.	13.7	1
581	Î²-Amyloid Induces Pathology-Related Patterns of Tau Hyperphosphorylation at Synaptic Terminals. Journal of Neuropathology and Experimental Neurology, 2018, 77, 814-826.	0.9	46
582	In Search of Darwin's Imaginary Gemmules. Advances in Genetics, 2018, 101, 87-114.	0.8	9
583	Prion infectivity is encoded exclusively within the structure of proteinase K-resistant fragments of synthetically generated recombinant PrPSc. Acta Neuropathologica Communications, 2018, 6, 30.	2.4	15
584	Discriminating Strains of Self-Propagating Protein Aggregates Using a Conformational Stability Assay. Methods in Molecular Biology, 2018, 1777, 339-354.	0.4	5
585	Tau Spreading Mechanisms; Implications for Dysfunctional Tauopathies. International Journal of Molecular Sciences, 2018, 19, 645.	1.8	36
586	Quinolinic Acid Amyloid-like Fibrillar Assemblies Seed Î±-Synuclein Aggregation. Journal of Molecular Biology, 2018, 430, 3847-3862.	2.0	43
587	Elongator mutation in mice induces neurodegeneration and ataxia-like behavior. Nature Communications, 2018, 9, 3195.	5.8	40
588	Transcellular Spreading of Tau in Tauopathies. ChemBioChem, 2018, 19, 2424-2432.	1.3	22

#	Article	IF	Citations
589	Depletion of mRNA export regulator DBP5/DDX19, GLE1 or IPPK that is a key enzyme for the production of IP6, resulting in differentially altered cytoplasmic mRNA expression and specific cell defect. PLoS ONE, 2018, 13, e0197165.	1.1	18
590	Left lateralized cerebral glucose metabolism declines in amyloid-Î² positive persons with mild cognitive impairment. NeuroImage: Clinical, 2018, 20, 286-296.	1.4	64
591	Prion-like Domains in Eukaryotic Viruses. Scientific Reports, 2018, 8, 8931.	1.6	43
592	Prion-like mechanisms in Alzheimer disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 153, 303-319.	1.0	42
593	Prion-like mechanisms in amyotrophic lateral sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 153, 337-354.	1.0	31
594	Noninfectious Disease Vaccines. , 2018, , 689-697.e4.		1
595	Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation. Molecular Neurobiology, 2019, 56, 3295-3312.	1.9	449
596	A bi-monomeric, nonlinear Beckerâ€“DÃ¶ring-type system to capture oscillatory aggregation kinetics in prion dynamics. Journal of Theoretical Biology, 2019, 480, 241-261.	0.8	3
597	Cytotoxic species in amyloid-associated diseases: Oligomers or mature fibrils. Advances in Protein Chemistry and Structural Biology, 2019, 118, 333-369.	1.0	26
598	Clinical implications of extracellular vesicles in neurodegenerative diseases. Expert Review of Molecular Diagnostics, 2019, 19, 813-824.	1.5	14
599	Examining the relationship between astrocyte dysfunction and neurodegeneration in ALS using hiPSCs. Neurobiology of Disease, 2019, 132, 104562.	2.1	20
601	Understanding biochemical processes in the presence of sub-diffusive behavior of biomolecules in solution and living cells. Biophysical Reviews, 2019, 11, 851-872.	1.5	12
602	The role of mutations associated with familial neurodegenerative disorders on bloodâ€“brain barrier function in an iPSC model. Fluids and Barriers of the CNS, 2019, 16, 20.	2.4	51
603	Exosomes from patients with Parkinsonâ€™s disease are pathological in mice. Journal of Molecular Medicine, 2019, 97, 1329-1344.	1.7	58
604	Diverse Misfolded Conformational Strains and Cross-seeding of Misfolded Proteins Implicated in Neurodegenerative Diseases. Frontiers in Molecular Neuroscience, 2019, 12, 158.	1.4	31
605	Organic Nanoscrolls from Electrostatic Interactions between Peptides and Lipids: Assembly Steps and Structure. Langmuir, 2019, 35, 10648-10657.	1.6	4
606	Connectomics of neurodegeneration. Nature Neuroscience, 2019, 22, 1200-1202.	7.1	5
607	Tuning the structure of monomeric amyloid beta peptide by the curvature of carbon nanotubes. Carbon, 2019, 153, 717-724.	5.4	14

#	Article	IF	Citations
608	High lithium levels in tobacco may account for reduced incidences of both Parkinsonâ€™s disease and melanoma in smokers through enhanced Î²-catenin-mediated activity. Medical Hypotheses, 2019, 131, 109302.	0.8	11
609	Isomerization of Asp7 in Beta-Amyloid Enhances Inhibition of the Î±7 Nicotinic Receptor and Promotes Neurotoxicity. Cells, 2019, 8, 771.	1.8	26
610	Age-Linked Non-Transmissible Diseases. Practical Issues in Geriatrics, 2019, , 59-82.	0.3	0
611	BIN1 favors the spreading of Tau via extracellular vesicles. Scientific Reports, 2019, 9, 9477.	1.6	107
613	Revealing Protein Aggregates under Thapsigargin-Induced ER Stress Using an ER-Targeted Thioflavin. ACS Sensors, 2019, 4, 2858-2863.	4.0	8
614	Prion-like spreading of Alzheimerâ€™s disease within the brainâ€™s connectome. Journal of the Royal Society Interface, 2019, 16, 20190356.	1.5	71
615	Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A2A receptor. Brain, 2019, 142, 3636-3654.	3.7	71
616	Early stage prion assembly involves two subpopulations with different quaternary structures and a secondary templating pathway. Communications Biology, 2019, 2, 363.	2.0	13
617	Inflammasomeâ€mediated innate immunity in Alzheimer's disease. FASEB Journal, 2019, 33, 13075-13084.	0.2	55
618	Prion-like propagation of Î±-synuclein in neurodegenerative diseases. Progress in Molecular Biology and Translational Science, 2019, 168, 323-348.	0.9	18
619	Impaired tauâ€“microtubule interactions are prevalent among pathogenic tau variants arising from missense mutations. Journal of Biological Chemistry, 2019, 294, 18488-18503.	1.6	23
620	Molecular mechanisms of proteinopathies across neurodegenerative disease: a review. Neurological Research and Practice, 2019, 1, 35.	1.0	33
621	CLVFFA-Functionalized Gold Nanoclusters Inhibit AÎ²40 Fibrillation, Fibrilsâ€™ Prolongation, and Mature Fibrilsâ€™ Disaggregation. ACS Chemical Neuroscience, 2019, 10, 4633-4642.	1.7	30
622	Structural Insights into Curli CsgA Cross-Î² Fibril Architecture Inspire Repurposing of Anti-amyloid Compounds as Anti-biofilm Agents. PLoS Pathogens, 2019, 15, e1007978.	2.1	62
623	Genetic Factors in Mammalian Prion Diseases. Annual Review of Genetics, 2019, 53, 117-147.	3.2	63
624	Shear-induced amyloid formation of IDPs in the brain. Progress in Molecular Biology and Translational Science, 2019, 166, 225-309.	0.9	9
625	Microbiome Influence in the Pathogenesis of Prion and Alzheimerâ€™s Diseases. International Journal of Molecular Sciences, 2019, 20, 4704.	1.8	42
626	Brain insulin response and peripheral metabolic changes in a Tau transgenic mouse model. Neurobiology of Disease, 2019, 125, 14-22.	2.1	16

#	Article	IF	Citations
627	Topological Analysis of Transthyretin Disassembly Mechanism: Surface-Induced Dissociation Reveals Hidden Reaction Pathways. Analytical Chemistry, 2019, 91, 2345-2351.	3.2	22
628	Hepatitis B and C virus infection as a risk factor for Parkinson's disease in Israel-A nationwide cohort study. Journal of the Neurological Sciences, 2019, 398, 138-141.	0.3	17
629	Aggregated Tau activates NLRP3â€“ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. Acta Neuropathologica, 2019, 137, 599-617.	3.9	259
630	Fluorescent silicon nanoparticles inhibit the amyloid fibrillation of insulin. Journal of Materials Chemistry B, 2019, 7, 1397-1403.	2.9	20
631	A brief history of antibody-based therapy. Neurobiology of Disease, 2019, 130, 104504.	2.1	8
632	Molecular insights into the surface-catalyzed secondary nucleation of amyloid-Î² ₄₀ (AÎ²) Tj ETQq1 1 0.784314 rgBT /Ove	4.7	54
633	Observing crystal nucleation in four dimensions using atomic electron tomography. Nature, 2019, 570, 500-503.	13.7	219
634	Pro-Inflammatory S100A9 Protein Aggregation Promoted by NCAM1 Peptide Constructs. ACS Chemical Biology, 2019, 14, 1410-1417.	1.6	13
635	Modeling and Inference of Spatio-Temporal Protein Dynamics Across Brain Networks. Lecture Notes in Computer Science, 2019, , 57-69.	1.0	9
636	Changing how we think about infectious diseases. , 2019, , 321-365.		3
637	Potential Value of Plasma Amyloid-Î², Total Tau, and Neurofilament Light for Identification of Early Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 3479-3485.	1.7	44
638	Evidence for Network-Based Cortical Thickness Reductions in Schizophrenia. American Journal of Psychiatry, 2019, 176, 552-563.	4.0	97
640	Î±-synuclein in the pathophysiology of Alzheimerâ€™s disease. Molecular Neurodegeneration, 2019, 14, 23.	4.4	197
641	Association Between Axonopathy and Amyloid Plaques in the Spinal Cord of the Transgenic Mice of Alzheimer's Disease. Neuroscience, 2019, 409, 152-161.	1.1	4
642	Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease. JAMA Neurology, 2019, 76, 969.	4.5	65
643	Spreading of Î±-Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved. Frontiers in Molecular Neuroscience, 2019, 12, 107.	1.4	79
644	Automated four-dimensional long term imaging enables single cell tracking within organotypic brain slices to study neurodevelopment and degeneration. Communications Biology, 2019, 2, 155.	2.0	28
645	Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium. Journal of the Neurological Sciences, 2019, 402, 121-130.	0.3	20

#	Article	IF	Citations
646	Modulating conformational stability of human serum albumin and implications for surface passivation applications. Colloids and Surfaces B: Biointerfaces, 2019, 180, 306-312.	2.5	11
647	The interplay of biochemical and biomechanical degeneration in Alzheimerâ€™s disease. Computer Methods in Applied Mechanics and Engineering, 2019, 352, 369-388.	3.4	23
648	Molecular structure of an N-terminal phosphorylated Î²-amyloid fibril. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11253-11258.	3.3	43
649	Ultravioletâ€“visibleâ€“near-infrared optical properties of amyloid fibrils shed light on amyloidogenesis. Nature Photonics, 2019, 13, 473-479.	15.6	69
650	Tunable regulatory activities of 1,10-phenanthroline derivatives towards acid sphingomyelinase and Zn(<scp>ii</scp>)â€“amyloid-Î². Chemical Communications, 2019, 55, 5847-5850.	2.2	5
651	Bassoon proteinopathy drives neurodegeneration in multiple sclerosis. Nature Neuroscience, 2019, 22, 887-896.	7.1	55
652	The Pathobiology of TDP-43 C-Terminal Fragments in ALS and FTLD. Frontiers in Neuroscience, 2019, 13, 335.	1.4	135
653	Distinct Binding Dynamics, Sites and Interactions of Fullerene and Fullerenols with Amyloid-Î² Peptides Revealed by Molecular Dynamics Simulations. International Journal of Molecular Sciences, 2019, 20, 2048.	1.8	28
654	Is Alzheimerâ€™s Disease Transmissible in Humans?. Neuroscience Bulletin, 2019, 35, 1113-1115.	1.5	5
655	Performance comparison of ab initio protein structure prediction methods. Ain Shams Engineering Journal, 2019, 10, 713-719.	3.5	7
656	Plasmalogens and Alzheimerâ€™s disease: a review. Lipids in Health and Disease, 2019, 18, 100.	1.2	99
657	Neurodegeneration and contralateral Î±-synuclein induction after intracerebral Î±-synuclein injections in the anterior olfactory nucleus of a Parkinsonâ€™s disease A53T mouse model. Acta Neuropathologica Communications, 2019, 7, 56.	2.4	13
658	Rapid Fragmentation during Seeded Lysozyme Aggregation Revealed at the Single Molecule Level. Analytical Chemistry, 2019, 91, 6880-6886.	3.2	7
659	Nanoscale Multiparametric Imaging of Peptide-Assembled Nanofibrillar Hydrogels by Atomic Force Microscopy. IEEE Nanotechnology Magazine, 2019, 18, 315-328.	1.1	9
660	Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in alzheimer disease. Annals of Neurology, 2019, 85, 726-739.	2.8	84
661	Comparative study of cerebrospinal fluid Î±â€synuclein seeding aggregation assays for diagnosis of Parkinson's disease. Movement Disorders, 2019, 34, 536-544.	2.2	146
662	Î±-Synuclein-derived lipoparticles in the study of Î±-Synuclein amyloid fibril formation. Chemistry and Physics of Lipids, 2019, 220, 57-65.	1.5	9
663	Anti-prion systems in yeast. Journal of Biological Chemistry, 2019, 294, 1729-1738.	1.6	18

#	Article	IF	Citations
664	Dural lymphatics regulate clearance of extracellular tau from the CNS. Molecular Neurodegeneration, 2019, 14, 11.	4.4	134
665	High-Pressure Response of Amyloid Folds. Viruses, 2019, 11, 202.	1.5	4
666	Direct observation of prion protein oligomer formation reveals an aggregation mechanism with multiple conformationally distinct species. Chemical Science, 2019, 10, 4588-4597.	3.7	22
667	Î±-Synuclein misfolding and aggregation: Implications in Parkinsonâ€™s disease pathogenesis. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2019, 1867, 890-908.	1.1	241
668	Phosphorylated and aggregated TDP-43 with seeding properties are induced upon mutant Huntingtin (mHtt) polyglutamine expression in human cellular models. Cellular and Molecular Life Sciences, 2019, 76, 2615-2632.	2.4	19
669	Amyloid-Î²: Can One Bad Apple Really Spoil the Whole Brain? Transmission of Amyloid-Î² Protein Pathology From Cadaveric Pituitary Growth Hormone. Neurosurgery, 2019, 85, E185-E187.	0.6	1
670	Atomic insight into prion disorder: An intricate detail gained by 0.5â€‰Î¼s molecular dynamics simulation of preventive G127V and deleterious D178V mutation in prion protein. Journal of Cellular Biochemistry, 2019, 120, 14156-14164.	1.2	2
671	LRRK2 modifies Î±-syn pathology and spread in mouse models and human neurons. Acta Neuropathologica, 2019, 137, 961-980.	3.9	142
672	Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. Neurobiology of Aging, 2019, 79, 131-141.	1.5	23
673	Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease. Progress in Brain Research, 2019, 245, 201-246.	0.9	28
674	Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms. Acta Neuropathologica, 2019, 137, 981-1001.	3.9	52
675	Innovative Therapy for Alzheimerâ€™s Disease-With Focus on Biodelivery of NGF. Frontiers in Neuroscience, 2019, 13, 38.	1.4	103
676	Structural connectivity centrality changes mark the path toward Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 98-107.	1.2	17
677	The primary neuronal cells are more resistant than PC12 cells to Î±-synuclein toxic aggregates. Neuroscience Letters, 2019, 701, 38-47.	1.0	11
678	Detection of Misfolded Î±-Synuclein Aggregates in Cerebrospinal Fluid by the Protein Misfolding Cyclic Amplification Platform. Methods in Molecular Biology, 2019, 1948, 35-44.	0.4	16
679	Precisely Defined Conjugated Oligoelectrolytes for Biosensing and Therapeutics. Advanced Materials, 2019, 31, e1806701.	11.1	57
680	Pathophysiology of Amyloid Fibril Formation. , 0, , .		1
681	Systemic Immune Response to Traumatic CNS Injuriesâ€”Are Extracellular Vesicles the Missing Link?. Frontiers in Immunology, 2019, 10, 2723.	2.2	37

#	Article	IF	Citations
682	Toxic Tau Oligomers Modulated by Novel Curcumin Derivatives. Scientific Reports, 2019, 9, 19011.	1.6	50
683	Deformation of stable and toxic hIAPP oligomers by liposomes with distinct nanomechanical features and reduced cytotoxicity. Chemical Communications, 2019, 55, 14359-14362.	2.2	8
684	Cytoplasmic Restriction of Mutated SOD1 Impairs the DNA Repair Process in Spinal Cord Neurons. Cells, 2019, 8, 1502.	1.8	18
685	InÂVivo Protein Complementation Demonstrates Presynaptic Î±-Synuclein Oligomerization and Age-Dependent Accumulation of 8â€“16-mer Oligomer Species. Cell Reports, 2019, 29, 2862-2874.e9.	2.9	26
686	Tanshinone IIA attenuates AÎ²-induced neurotoxicity by down-regulating COX-2 expression and PGE2 synthesis via inactivation of NF-ÎºB pathway in SH-SY5Y cells. Journal of Biological Research, 2019, 26, 15.	2.2	12
687	Local vulnerability and global connectivity jointly shape neurodegenerative disease propagation. PLoS Biology, 2019, 17, e3000495.	2.6	79
688	Combining molecular dynamics simulations and experimental analyses in protein misfolding. Advances in Protein Chemistry and Structural Biology, 2019, 118, 33-110.	1.0	9
689	Bifunctional ligand design for modulating mutant p53 aggregation in cancer. Chemical Science, 2019, 10, 10802-10814.	3.7	30
690	2â€²,3â€²-Dideoxycytidine, a DNA Polymerase-Î² Inhibitor, Reverses Memory Deficits in a Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 67, 515-525.	1.2	13
691	SUMOylation and the HSF1-Regulated Chaperone Network Converge to Promote Proteostasis in Response to Heat Shock. Cell Reports, 2019, 26, 236-249.e4.	2.9	44
692	Iron-related nigral degeneration influences functional topology mediated by striatal dysfunction in Parkinson's disease. Neurobiology of Aging, 2019, 75, 83-97.	1.5	35
693	X-ray crystallographic analysis of time-dependent binding of guanidine hydrochloride to HEWL: First steps during protein unfolding. International Journal of Biological Macromolecules, 2019, 122, 903-913.	3.6	22
694	The Anti-amyloid Compound DO1 Decreases Plaque Pathology and Neuroinflammation-Related Expression Changes in 5xFAD Transgenic Mice. Cell Chemical Biology, 2019, 26, 109-120.e7.	2.5	8
695	Review: PrP 106â€126 â€“ 25 years after. Neuropathology and Applied Neurobiology, 2019, 45, 430-440.	1.8	19
696	Editorial: Network Spread Models of Neurodegenerative Diseases. Frontiers in Neurology, 2018, 9, 1159.	1.1	6
697	Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. Nature Neuroscience, 2019, 22, 191-204.	7.1	358
698	Fibril formation and therapeutic targeting of amyloid-like structures in a yeast model of adenine accumulation. Nature Communications, 2019, 10, 62.	5.8	48
699	Brain-Gut-Microbiota Axis in Alzheimerâ€™s Disease. Journal of Neurogastroenterology and Motility, 2019, 25, 48-60.	0.8	496

#	Article	IF	Citations
701	Tau PET imaging in neurodegenerative tauopathiesâ€”still a challenge. Molecular Psychiatry, 2019, 24, 1112-1134.	4.1	409
702	Transthyretin Aggregation Pathway toward the Formation of Distinct Cytotoxic Oligomers. Scientific Reports, 2019, 9, 33.	1.6	41
703	Neurotheranostics as personalized medicines. Advanced Drug Delivery Reviews, 2019, 148, 252-289.	6.6	63
704	A physics-based model explains the prion-like features of neurodegeneration in Alzheimerâ€™s disease, Parkinsonâ€™s disease, and amyotrophic lateral sclerosis. Journal of the Mechanics and Physics of Solids, 2019, 124, 264-281.	2.3	83
705	Disturbances of sleep quality, timing and structure and their relationship with other neuropsychiatric symptoms in Alzheimerâ€™s disease and schizophrenia: Insights from studies in patient populations and animal models. Neuroscience and Biobehavioral Reviews, 2019, 97, 112-137.	2.9	56
706	DNP-Assisted NMR Investigation of Proteins at Endogenous Levels in Cellular Milieu. Methods in Enzymology, 2019, 615, 373-406.	0.4	14
707	Rational Structureâ€Based Design of Fluorescent Probes for Amyloid Folds. ChemBioChem, 2019, 20, 1161-1166.	1.3	5
708	The Prion Diseases. , 2019, , 123-155.		0
709	Huntingtonâ€™s Chorea. , 2019, , 193-219.		0
710	Role of Rab GTPases in Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2019, 10, 828-838.	1.7	27
711	AÎ² oligomers trigger and accelerate AÎ² seeding. Brain Pathology, 2020, 30, 36-45.	2.1	62
712	Changes in functional and structural brain connectome along the Alzheimerâ€™s disease continuum. Molecular Psychiatry, 2020, 25, 230-239.	4.1	78
714	Prion-like p53 Amyloids in Cancer. Biochemistry, 2020, 59, 146-155.	1.2	42
715	Fifty Shades of Brain: A Review on the Mechanical Testing and Modeling of Brain Tissue. Archives of Computational Methods in Engineering, 2020, 27, 1187-1230.	6.0	215
716	Multimodal ¹⁸F-AV-1451 and MRI Findings in Nonfluent Variant of Primary Progressive Aphasia: Possible Insights on Nodal Propagation of Tau Protein Across the Syntactic Network. Journal of Nuclear Medicine, 2020, 61, 263-269.	2.8	7
717	The apparent mechanical effect of isolated amyloidâ€Îˆ² and Î±â€synuclein aggregates revealed by multiâ€frequency MRE. NMR in Biomedicine, 2020, 33, e4174.	1.6	12
718	Mechanisms of secretion and spreading of pathological tau protein. Cellular and Molecular Life Sciences, 2020, 77, 1721-1744.	2.4	174
719	From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. Acta Neuropathologica, 2020, 139, 3-25.	3.9	134

#	Article	IF	Citations
720	Electrostatic Complementarity Drives Amyloid/Nucleic Acid Coâ€Assembly. Angewandte Chemie - International Edition, 2020, 59, 358-363.	7.2	29
721	Electrostatic Complementarity Drives Amyloid/Nucleic Acid Coâ€Assembly. Angewandte Chemie, 2020, 132, 366-371.	1.6	8
722	Modeling the life cycle of the human brain. Current Opinion in Biomedical Engineering, 2020, 15, 16-25.	1.8	13
723	Peptides Co-Assembling into Hydrangea-Like Microstructures. Journal of Nanoscience and Nanotechnology, 2020, 20, 3239-3245.	0.9	1
724	Protein aggregate formation permits millennium-old brain preservation. Journal of the Royal Society Interface, 2020, 17, 20190775.	1.5	11
725	Promoting tau secretion and propagation by hyperactive p300/CBP via autophagy-lysosomal pathway in tauopathy. Molecular Neurodegeneration, 2020, 15, 2.	4.4	69
726	Focusing of sub-micrometer particles in microfluidic devices. Lab on A Chip, 2020, 20, 35-53.	3.1	77
727	Association between SNCA rs356220 polymorphism and Parkinsonâ€™s disease: A meta-analysis. Neuroscience Letters, 2020, 717, 134703.	1.0	6
728	Metal homeostasis disturbances in neurodegenerative disorders, with special emphasis on Creutzfeldt-Jakob disease â€“ Potential pathogenetic mechanism and therapeutic implications. , 2020, 207, 107455.		7
729	Hypoxic-conditioned medium from adipose tissue mesenchymal stem cells improved neuroinflammation through alternation of toll like receptor (TLR) 2 and TLR4 expression in model of Alzheimer's disease rats. Behavioural Brain Research, 2020, 379, 112362.	1.2	27
730	Decontamination of prions. , 2020, , 395-418.		0
731	Spatially-extended nucleation-aggregation-fragmentation models for the dynamics of prion-like neurodegenerative protein-spreading in the brain and its connectome. Journal of Theoretical Biology, 2020, 486, 110102.	0.8	35
732	Interactions between Soluble Species of Î²-Amyloid and Î±-Synuclein Promote Oligomerization while Inhibiting Fibrillization. Biochemistry, 2020, 59, 425-435.	1.2	20
733	Deficiency of the serine peptidase Kallikrein 6 does not affect the levels and the pathological accumulation of aâ€synuclein in mouse brain. Journal of Neurochemistry, 2020, 157, 2024-2038.	2.1	5
734	Glymphatic failure as a final common pathway to dementia. Science, 2020, 370, 50-56.	6.0	435
735	Quantifying the Role of Lysine in Prion Replication by Nano-LC Mass Spectrometry and Bioassay. Frontiers in Bioengineering and Biotechnology, 2020, 8, 562953.	2.0	2
736	One or more Î²-amyloid(s)? New insights into the prion-like nature of Alzheimer's disease. Progress in Molecular Biology and Translational Science, 2020, 175, 213-237.	0.9	1
737	The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies. Experimental and Molecular Medicine, 2020, 52, 1652-1662.	3.2	142

#	Article	IF	Citations
738	The Cell Biology of Tau Secretion. Frontiers in Molecular Neuroscience, 2020, 13, 569818.	1.4	28
739	Molecular Chaperones: A Double-Edged Sword in Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 2020, 12, 581374.	1.7	58
740	Risk of Transmissibility From Neurodegenerative Disease-Associated Proteins: Experimental Knowns and Unknowns. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1141-1146.	0.9	24
741	Bushen-Tiansui Formula Improves Cognitive Functions in an AÎ²1â€“42 Fibril-Infused Rat Model of Alzheimerâ€™s Disease. Neural Plasticity, 2020, 2020, 1-11.	1.0	4
742	Anisotropic diffusion and traveling waves of toxic proteins in neurodegenerative diseases. Physics Letters, Section A: General, Atomic and Solid State Physics, 2020, 384, 126935.	0.9	5
743	Protein-protein interactions in neurodegenerative diseases: A conspiracy theory. PLoS Computational Biology, 2020, 16, e1008267.	1.5	35
744	Neurodegenerative disease-associated protein aggregates are poor inducers of the heat shock response in neuronal cells. Journal of Cell Science, 2020, 133, .	1.2	6
745	Studying the Pathophysiology of Parkinsonâ€™s Disease Using Zebrafish. Biomedicines, 2020, 8, 197.	1.4	24
746	Blood cell-produced amyloid-Î² induces cerebral Alzheimer-type pathologies and behavioral deficits. Molecular Psychiatry, 2021, 26, 5568-5577.	4.1	32
747	Î±-Synuclein aggregation and transmission in Parkinsonâ€™s disease: a link to mitochondria and lysosome. Science China Life Sciences, 2020, 63, 1850-1859.	2.3	16
748	The diverse role of optineurin in pathogenesis of disease. Biochemical Pharmacology, 2020, 180, 114157.	2.0	4
749	Clustering of human prion protein and Î±-synuclein oligomers requires the prion protein N-terminus. Communications Biology, 2020, 3, 365.	2.0	26
750	Communicability distance reveals hidden patterns of Alzheimerâ€™s disease. Network Neuroscience, 2020, 4, 1007-1029.	1.4	13
751	Fate and propagation of endogenously formed Tau aggregates in neuronal cells. EMBO Molecular Medicine, 2020, 12, e12025.	3.3	41
752	Manganese Exposure Aggravates Î²-Amyloid Pathology by Microglial Activation. Frontiers in Aging Neuroscience, 2020, 12, 556008.	1.7	20
753	Sporadic Creutzfeldt-Jakob Disease and Other Proteinopathies in Comorbidity. Frontiers in Neurology, 2020, 11, 596108.	1.1	6
754	Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimerâ€™s Disease. Cell, 2020, 183, 1699-1713.e13.	13.5	354
755	TRIM11 Prevents and Reverses Protein Aggregation and Rescues a Mouse Model of Parkinsonâ€™s Disease. Cell Reports, 2020, 33, 108418.	2.9	39

#	Article	IF	Citations
756	Autophagy alleviates hypoxia-induced blood-brain barrier injury via regulation of CLDN5 (claudin 5). Autophagy, 2021, 17, 3048-3067.	4.3	70
757	Transmissible Endosomal Intoxication: A Balance between Exosomes and Lysosomes at the Basis of Intercellular Amyloid Propagation. Biomedicines, 2020, 8, 272.	1.4	18
758	Role of tau protein in Alzheimer's disease: The prime pathological player. International Journal of Biological Macromolecules, 2020, 163, 1599-1617.	3.6	100
759	Direct measurement of lipid membrane disruption connects kinetics and toxicity of AÎ²42 aggregation. Nature Structural and Molecular Biology, 2020, 27, 886-891.	3.6	38
760	Structural effects of the highly protective V127 polymorphism on human prion protein. Communications Biology, 2020, 3, 402.	2.0	5
761	Novel MRI Techniques Identifying Vascular Leak and Paravascular Flow Reduction in Early Alzheimer Disease. Biomedicines, 2020, 8, 228.	1.4	15
762	Non-Invasive RF Technique for Detecting Different Stages of Alzheimerâ€™s Disease and Imaging Beta-Amyloid Plaques and Tau Tangles in the Brain. IEEE Transactions on Medical Imaging, 2020, 39, 4060-4070.	5.4	20
763	Circadian alterations in patients with neurodegenerative diseases: Neuropathological basis of underlying network mechanisms. Neurobiology of Disease, 2020, 144, 105029.	2.1	28
764	The existence of AÎ² strains and their potential for driving phenotypic heterogeneity in Alzheimerâ€™s disease. Acta Neuropathologica, 2021, 142, 17-39.	3.9	35
765	In vivo Retinal Fluorescence Imaging With Curcumin in an Alzheimer Mouse Model. Frontiers in Neuroscience, 2020, 14, 713.	1.4	34
766	A â€œketo-enolâ€•plaque buster mechanism to diminish Alzheimerâ€™s Î²-Amyloid burden. Biochemical and Biophysical Research Communications, 2020, 532, 82-87.	1.0	2
767	A conscious rethink: Why is brain tissue commonly preserved in the archaeological record? Commentary on: Petrone P, Pucci P, Niola M, et al. Heat-induced brain vitrification from the Vesuvius eruption in C.E. 79. N Engl J Med 2020;382:383-4. DOI: 10.1056/NEJMc1909867. Science and Technology of Archaeological Research, 2020, 6, 87-95.	2.4	2
768	Fast kinetics of environmentally induced Î±-synuclein aggregation mediated by structural alteration in NAC region and result in structure dependent cytotoxicity. Scientific Reports, 2020, 10, 18412.	1.6	18
769	Presence of intrinsically disordered proteins can inhibit the nucleation phase of amyloid fibril formation of AÎ²(1â€“42) in amino acid sequence independent manner. Scientific Reports, 2020, 10, 12334.	1.6	12
770	Quantification of amyloid fibril polymorphism by nano-morphometry reveals the individuality of filament assembly. Communications Chemistry, 2020, 3, .	2.0	25
771	Dietary Intake of Rosmarinic Acid Increases Serum Inhibitory Activity in Amyloid A Aggregation and Suppresses Deposition in the Organs of Mice. International Journal of Molecular Sciences, 2020, 21, 6031.	1.8	9
772	Mechanisms of Pathogenic Tau and AÎ² Protein Spreading in Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2020, 12, 265.	1.7	78
773	C. elegans Models to Study the Propagation of Prions and Prion-Like Proteins. Biomolecules, 2020, 10, 1188.	1.8	7

#	Article	IF	Citations
774	Anticoagulants for Treatment of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 77, 1373-1382.	1.2	15
775	Phenotypic diversity in ALS and the role of poly-conformational protein misfolding. Acta Neuropathologica, 2020, 142, 41-55.	3.9	9
776	Diffusion Tensor Imaging-Based Studies at the Group-Level Applied to Animal Models of Neurodegenerative Diseases. Frontiers in Neuroscience, 2020, 14, 734.	1.4	7
777	Structural and functional brain connectome in motor neuron diseases. Neurology, 2020, 95, e2552-e2564.	1.5	34
778	Novel Mode of Noncrystallographic Branching in the Initial Stages of Polymer Fibril Growth. Physical Review Letters, 2020, 125, 247801.	2.9	4
779	Contributions of Molecular and Optical Techniques to the Clinical Diagnosis of Alzheimerâ€™s Disease. Brain Sciences, 2020, 10, 815.	1.1	6
780	Amyotrophic Lateral Sclerosis and Autophagy: Dysfunction and Therapeutic Targeting. Cells, 2020, 9, 2413.	1.8	41
781	Investigating APOE, APP-AÎ² metabolism genes and Alzheimerâ€™s disease GWAS hits in brain small vessel ischemic disease. Scientific Reports, 2020, 10, 7103.	1.6	12
782	Evidence for the spread of human-derived mutant huntingtin protein in mice and non-human primates. Neurobiology of Disease, 2020, 141, 104941.	2.1	11
783	Self-Coiling of Single-Stranded Protofibrils into Rings: A Pathway of Alzheimerâ€™s Î²-Peptide Amyloidosis on Lipid Membranes. ACS Macro Letters, 2020, 9, 813-818.	2.3	7
784	Aggregation and Amyloidogenicity of the Nuclear Coactivator Binding Domain of CREBâ€Binding Protein. Chemistry - A European Journal, 2020, 26, 9889-9899.	1.7	6
785	Nanoscale analysis of protein self-assemblies. , 2020, , 249-268.		2
786	Epigenetic regulation in the pathophysiology of Lewy body dementia. Progress in Neurobiology, 2020, 192, 101822.	2.8	10
787	Interaction of the chaperones alpha B-crystallin and CHIP with fibrillar alpha-synuclein: Effects on internalization by cells and identification of interacting interfaces. Biochemical and Biophysical Research Communications, 2020, 527, 760-769.	1.0	8
788	Editorial: Tau Propagation Mechanisms: Cell Models, Animal Models, and Beyond. Frontiers in Neuroscience, 2020, 14, 456.	1.4	1
789	Engineered Extracellular Vesicles/Exosomes as a New Tool against Neurodegenerative Diseases. Pharmaceutics, 2020, 12, 529.	2.0	11
790	Efficient suppression of amyloid-Î² peptide aggregation and cytotoxicity with photosensitive polymer nanodots. Journal of Materials Chemistry B, 2020, 8, 5776-5782.	2.9	11
791	Biophysical studies of protein misfolding and aggregation inin vivomodels of Alzheimer's and Parkinson's diseases. Quarterly Reviews of Biophysics, 2020, 53, e22.	2.4	13

#	Article	IF	Citations
792	Binding modes of thioflavin T and Congo red to the fibril structure of amyloid-Î²(1â€“42). Chemical Communications, 2020, 56, 7589-7592.	2.2	38
793	The human olfactory system in two proteinopathies: Alzheimerâ€™s and Parkinsonâ€™s diseases. Translational Neurodegeneration, 2020, 9, 22.	3.6	62
794	Pneumonia-induced endothelial amyloids reduce dendritic spine density in brain neurons. Scientific Reports, 2020, 10, 9327.	1.6	10
795	Shedding a new light on Huntingtonâ€™s disease: how blood can both propagate and ameliorate disease pathology. Molecular Psychiatry, 2021, 26, 5441-5463.	4.1	16
796	Non-motor Clinical and Biomarker Predictors Enable High Cross-Validated Accuracy Detection of Early PD but Lesser Cross-Validated Accuracy Detection of Scans Without Evidence of Dopaminergic Deficit. Frontiers in Neurology, 2020, 11, 364.	1.1	7
797	Disentangling the Amyloid Pathways: A Mechanistic Approach to Etiology. Frontiers in Neuroscience, 2020, 14, 256.	1.4	21
798	Non-polyphenolic natural inhibitors of amyloid aggregation. European Journal of Medicinal Chemistry, 2020, 192, 112197.	2.6	44
799	Role of dietary fatty acids in microglial polarization in Alzheimerâ€™s disease. Journal of Neuroinflammation, 2020, 17, 93.	3.1	57
800	Formation of distinct prion protein amyloid fibrils under identical experimental conditions. Scientific Reports, 2020, 10, 4572.	1.6	23
801	Molecular Spectroscopic Markers of Abnormal Protein Aggregation. Molecules, 2020, 25, 2498.	1.7	24
802	Banhasasim-Tang Attenuates Lipopolysaccharide-Induced Cognitive Impairment by Suppressing Neuroinflammation in Mice. Nutrients, 2020, 12, 2019.	1.7	7
803	Milk Processing Affects Structure, Bioavailability and Immunogenicity of Î²-lactoglobulin. Foods, 2020, 9, 874.	1.9	30
804	Expression and Functional Study of Single Mutations of Carbonic Anhydrase 8 in Neuronal Cells. Cellular and Molecular Neurobiology, 2020, 41, 1355-1371.	1.7	2
805	In Silico Study of the Mechanism of Binding of the N-Terminal Region of Î± Synuclein to Synaptic-Like Membranes. Life, 2020, 10, 98.	1.1	7
806	Genetic Dissection of Alzheimerâ€™s Disease Using Drosophila Models. International Journal of Molecular Sciences, 2020, 21, 884.	1.8	27
807	Autophagy and Cell Death in Alzheimerâ€™s, Parkinsonâ€™s and Prion Diseases. , 2020, , .		1
808	Entropic Bristles Tune the Seeding Efficiency of Prion-Nucleating Fragments. Cell Reports, 2020, 30, 2834-2845.e3.	2.9	12
809	Bacterial DNA promotes Tau aggregation. Scientific Reports, 2020, 10, 2369.	1.6	43

#	Article	IF	Citations
810	Sclerotiorin Stabilizes the Assembly of Nonfibrillar Abeta42 Oligomers with Low Toxicity, Seeding Activity, and Beta-sheet Content. Journal of Molecular Biology, 2020, 432, 2080-2098.	2.0	12
811	Advanced neuroimaging approaches in amyotrophic lateral sclerosis: refining the clinical diagnosis. Expert Review of Neurotherapeutics, 2020, 20, 237-249.	1.4	22
812	Intracerebral seeding of amyloid-Î² and tau pathology in mice: Factors underlying prion-like spreading and comparisons with Î±-synuclein. Neuroscience and Biobehavioral Reviews, 2020, 112, 1-27.	2.9	31
813	The N-terminal Acetylation of Î±-Synuclein Changes the Affinity for Lipid Membranes but not the Structural Properties of the Bound State. Scientific Reports, 2020, 10, 204.	1.6	47
814	Identification of Key Regulatory Genes and Pathways in Prefrontal Cortex of Alzheimerâ€™s Disease. Interdisciplinary Sciences, Computational Life Sciences, 2020, 12, 90-98.	2.2	25
815	Engineered Î²-hairpin scaffolds from human prion protein regions: Structural and functional investigations of aggregates. Bioorganic Chemistry, 2020, 96, 103594.	2.0	10
816	Misfolded amyloid-Î²-42 impairs the endosomalâ€“lysosomal pathway. Cellular and Molecular Life Sciences, 2020, 77, 5031-5043.	2.4	36
817	Prevalence in Britain of abnormal prion protein in human appendices before and after exposure to the cattle BSE epizootic. Acta Neuropathologica, 2020, 139, 965-976.	3.9	30
818	New Insights into the Molecular Bases of Familial Alzheimerâ€™s Disease. Journal of Personalized Medicine, 2020, 10, 26.	1.1	19
819	Avidity within the Nâ€terminal anchor drives Î±â€synuclein membrane interaction and insertion. FASEB Journal, 2020, 34, 7462-7482.	0.2	28
820	Diversity in AÎ² deposit morphology and secondary proteome insolubility across models of Alzheimer-typeÂamyloidosis. Acta Neuropathologica Communications, 2020, 8, 43.	2.4	16
821	A combination of lycopene and human amniotic epithelial cells can ameliorate cognitive deficits and suppress neuroinflammatory signaling by choroid plexus in Alzheimer's disease rat. Journal of Nutritional Biochemistry, 2021, 88, 108558.	1.9	22
822	Tissue-specific features of microglial innate immune responses. Neurochemistry International, 2021, 142, 104924.	1.9	8
823	Comparison between touchscreen operant chambers and water maze to detect early prefrontal dysfunction in mice. Genes, Brain and Behavior, 2021, 20, e12695.	1.1	10
824	Proteins and Disease | Prions of Yeast and Fungi: Proteins Acting as Genes. , 2021, , 86-91.		0
825	Peripherally misfolded proteins exacerbate ischemic stroke-induced neuroinflammation and brain injury. Journal of Neuroinflammation, 2021, 18, 29.	3.1	12
826	Hierarchical chemical determination of amyloid polymorphs in neurodegenerative disease. Nature Chemical Biology, 2021, 17, 237-245.	3.9	66
827	The differential solvent exposure of N-terminal residues provides â€œfingerprintsâ€•of alpha-synuclein fibrillar polymorphs. Journal of Biological Chemistry, 2021, 296, 100737.	1.6	22

#	Article	IF	Citations
829	Molecular Mechanisms of Distinct Diseases. , 0, , .		0
831	Circadian and Sleep Dysfunctions in Neurodegenerative Disordersâ€"An Update. Frontiers in Neuroscience, 2020, 14, 627330.	1.4	33
832	ProTG4: A Web Server to Approximate the Sequence of a Generic Protein From an in Silico Library of Translatable G-Quadruplex (TG4)-Mapped Peptides. Bioinformatics and Biology Insights, 2021, 15, 117793222110458.	1.0	0
833	Is Î³-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?. Journal of Biological Chemistry, 2021, 296, 100489.	1.6	32
834	p53, A Victim of the Prion Fashion. Cancers, 2021, 13, 269.	1.7	8
835	Absence of Uptake and Prion-Like Spreading of Alpha-Synuclein and Tau After Intravitreal Injection of Preformed Fibrils. Frontiers in Aging Neuroscience, 2020, 12, 614587.	1.7	7
836	Pathobiolgy and Management of Alzheimer's Disease. Chonnam Medical Journal, 2021, 57, 108.	0.5	4
837	Impact of Tau on Neurovascular Pathology in Alzheimer's Disease. Frontiers in Neurology, 2020, 11, 573324.	1.1	24
838	Shear-Induced Amyloid Aggregation in the Brain: V. Are Alzheimerâ€™s and Other Amyloid Diseases Initiated in the Lower Brain and Brainstem by Cerebrospinal Fluid Flow Stresses?. Journal of Alzheimer's Disease, 2021, 79, 979-1002.	1.2	8
839	Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimerâ€™s Disease, Parkinsonâ€™s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis. Chemical Reviews, 2021, 121, 2545-2647.	23.0	406
841	Comparative analysis of heparin affecting the biochemical properties of chicken and murine prion proteins. PLoS ONE, 2021, 16, e0247248.	1.1	0
842	Learning Deficits Accompanied by Microglial Proliferation After the Long-Term Post-Injection of Alzheimerâ€™s Disease Brain Extract in Mouse Brains. Journal of Alzheimer's Disease, 2021, 79, 1701-1711.	1.2	3
843	Structural analysis of the Î²â€sheet edge of peptide selfâ€assembly using a model protein. Proteins: Structure, Function and Bioinformatics, 2021, 89, 845-852.	1.5	3
844	Remodeling Alzheimer-amyloidosis models by seeding. Molecular Neurodegeneration, 2021, 16, 8.	4.4	7
846	Complex Inclusion Bodies and Defective Proteome Hubs in Neurodegenerative Disease: New Clues, New Challenges. Neuroscientist, 2022, 28, 271-282.	2.6	5
847	Coâ€occurrence of idiopathic normalâ€pressure hydrocephalusâ€like magnetic resonance imaging features in progressive supranuclear palsy. European Journal of Neurology, 2021, 28, e48-e49.	1.7	0
848	Fatal Attraction: The Case of Toxic Soluble Dimers of Truncated PQBP-1 Mutants in X-Linked Intellectual Disability. International Journal of Molecular Sciences, 2021, 22, 2240.	1.8	1
849	Pericytes and the Neurovascular Unit: The Critical Nexus of Alzheimer Disease Pathogenesis?. Exploratory Research and Hypothesis in Medicine, 2021, 000, 000-000.	0.1	0

#	Article	IF	Citations
850	Neuropathology of Animal Prion Diseases. Biomolecules, 2021, 11, 466.	1.8	18
851	Insight Into Seeded Tau Fibril Growth From Molecular Dynamics Simulation of the Alzheimerâ€™s Disease Protofibril Core. Frontiers in Molecular Biosciences, 2021, 8, 624302.	1.6	17
852	Triad of TDP43 control in neurodegeneration: autoregulation, localization and aggregation. Nature Reviews Neuroscience, 2021, 22, 197-208.	4.9	107
853	Spreading of Beta-Amyloid in Organotypic Mouse Brain Slices and Microglial Elimination and Effects on Cholinergic Neurons. Biomolecules, 2021, 11, 434.	1.8	10
854	Prionopathies and Prionlike Protein Aberrations in Neurodegenerative Diseases. Neurographics, 2021, 11, 127-148.	0.0	0
855	Quantitative Assessment of Occipital Metabolic and Energetic Changes in Parkinsonâ€™s Patients, Using In Vivo 31P MRS-Based Metabolic Imaging at 7T. Metabolites, 2021, 11, 145.	1.3	11
856	Super-resolving Microscopy in Neuroscience. Chemical Reviews, 2021, 121, 11971-12015.	23.0	40
857	Evaluation of blood flow as a route for propagation in experimental synucleinopathy. Neurobiology of Disease, 2021, 150, 105255.	2.1	5
858	Human tauopathy-derived tau strains determine the substrates recruited for templated amplification. Brain, 2021, 144, 2333-2348.	3.7	17
859	Asymmetric Amyloid Deposition as an Early Sign of Progression in Mild Cognitive Impairment Due to Alzheimer Disease. Clinical Nuclear Medicine, 2021, 46, 527-531.	0.7	6
861	Perampanel Inhibits Î±â€Synuclein Transmission in Parkinson's Disease Models. Movement Disorders, 2021, 36, 1554-1564.	2.2	21
862	Alzheimerâ€™s Diseaseâ€”Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran. International Journal of Molecular Sciences, 2021, 22, 4805.	1.8	13
863	Prion potentiation after life-long dormancy in mice devoid of PrP. Brain Communications, 2021, 3, fcab092.	1.5	9
864	The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial. Brain, 2021, 144, 2635-2647.	3.7	33
865	Acetylated tau inhibits chaperone-mediated autophagy and promotes tau pathology propagation in mice. Nature Communications, 2021, 12, 2238.	5.8	101
866	Parallel and antiparallel peptide double Î²â€helices controlled by metalâ€induced folding and assembly. Natural Sciences, 2021, 1, e10008.	1.0	12
867	Dysbiosis and Alzheimerâ€™s Disease: A Role for Chronic Stress?. Biomolecules, 2021, 11, 678.	1.8	51
868	In situ architecture of neuronal Î±-Synuclein inclusions. Nature Communications, 2021, 12, 2110.	5.8	66

#	Article	IF	Citations
869	Tau induces formation of Î±-synuclein filaments with distinct molecular conformations. Biochemical and Biophysical Research Communications, 2021, 554, 145-150.	1.0	13
870	Understanding amphisomes. Biochemical Journal, 2021, 478, 1959-1976.	1.7	57
871	Graph Models of Pathology Spread in Alzheimer's Disease: An Alternative to Conventional Graph Theoretic Analysis. Brain Connectivity, 2021, 11, 799-814.	0.8	9
872	Karyopherin abnormalities in neurodegenerative proteinopathies. Brain, 2021, 144, 2915-2932.	3.7	20
873	AÎ²43 aggregates exhibit enhanced prion-like seeding activity in mice. Acta Neuropathologica Communications, 2021, 9, 83.	2.4	14
874	Differentially expressed genes in Alzheimerâ€™s disease highlighting the roles of microglia genes including OLR1 and astrocyte gene CDK2AP1. Brain, Behavior, & Immunity - Health, 2021, 13, 100227.	1.3	28
875	Structural And Computational Perspectives of Selectively Targeting Mutant Proteins. Current Drug Discovery Technologies, 2021, 18, 365-378.	0.6	4
876	Role of the endolysosomal pathway and exosome release in tau propagation. Neurochemistry International, 2021, 145, 104988.	1.9	9
878	How an Infection of Sheep Revealed Prion Mechanisms in Alzheimerâ€™s Disease and Other Neurodegenerative Disorders. International Journal of Molecular Sciences, 2021, 22, 4861.	1.8	25
879	Traceable Nanoâ€Biohybrid Complexes by Oneâ€Step Synthesis as CRISPRâ€Chem Vectors for Neurodegenerative Diseases Synergistic Treatment. Advanced Materials, 2021, 33, e2101993.	11.1	20
880	Selective vulnerability to atrophy in sporadic Creutzfeldtâ€Jakob disease. Annals of Clinical and Translational Neurology, 2021, 8, 1183-1199.	1.7	4
881	Transmission of cerebral amyloid pathology by peripheral administration of misfolded AÎ² aggregates. Molecular Psychiatry, 2021, 26, 5690-5701.	4.1	18
882	Mitophagy and Oxidative Stress: The Role of Aging. Antioxidants, 2021, 10, 794.	2.2	59
883	Mechanisms That Activate 26S Proteasomes and Enhance Protein Degradation. Biomolecules, 2021, 11, 779.	1.8	19
885	Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimerâ€™s disease lead to depression?. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 841-856.	1.5	22
886	Protein Predictive Modeling and Simulation of Mutations of Presenilin-1 Familial Alzheimerâ€™s Disease on the Orthosteric Site. Frontiers in Molecular Biosciences, 2021, 8, 649990.	1.6	3
887	Complicity of Î±-synuclein oligomer and calcium dyshomeostasis in selective neuronal vulnerability in Lewy body disease. Archives of Pharmacal Research, 2021, 44, 564-573.	2.7	1
888	Spontaneous formation of Î²-sheet nano-barrels during the early aggregation of Alzheimerâ€™s amyloid beta. Nano Today, 2021, 38, 101125.	6.2	44

#	Article	IF	Citations
889	Tackling prion diseases: a review of the patent landscape. Expert Opinion on Therapeutic Patents, 2021, 31, 1097-1115.	2.4	10
890	Understanding the Role of Protein Glycation in the Amyloid Aggregation Process. International Journal of Molecular Sciences, 2021, 22, 6609.	1.8	31
891	Bacterial Extracellular DNA Promotes Î²-Amyloid Aggregation. Microorganisms, 2021, 9, 1301.	1.6	19
892	Direct evidence of cellular transformation by prion-like p53 amyloid infection. Journal of Cell Science, 2021, 134, .	1.2	15
893	Movement of prionâ€like Î±â€synuclein along the gutâ€“brain axis in Parkinson's disease: A potential target of curcumin treatment. European Journal of Neuroscience, 2021, 54, 4695-4711.	1.2	14
894	Refining the amyloid Î² peptide and oligomer fingerprint ambiguities in Alzheimerâ€™s disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma. Journal of Neurochemistry, 2021, 159, 234-257.	2.1	8
895	Central Nervous System Cell-Derived Exosomes in Neurodegenerative Diseases. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-11.	1.9	12
896	Combined Model of Aggregation and Network Diffusion Recapitulates Alzheimer's Regional Tau-Positron Emission Tomography. Brain Connectivity, 2021, 11, 624-638.	0.8	8
897	Dysfunctional Brain Dynamics of Parkinson's Disease and the Effect of Acute Deep Brain Stimulation. Frontiers in Neuroscience, 2021, 15, 697909.	1.4	3
898	Molecular Communication Between Neuronal Networks and Intestinal Epithelial Cells in Gut Inflammation and Parkinson's Disease. Frontiers in Medicine, 2021, 8, 655123.	1.2	11
899	Post-Translational Modifications Modulate Proteinopathies of TDP-43, FUS and hnRNP-A/B in Amyotrophic Lateral Sclerosis. Frontiers in Molecular Biosciences, 2021, 8, 693325.	1.6	16
900	The potential role of glial cells in driving the prion-like transcellular propagation of tau in tauopathies. Brain, Behavior, & Immunity - Health, 2021, 14, 100242.	1.3	14
901	Possible Mechanisms of Tau Spread and Toxicity in Alzheimerâ€™s Disease. Frontiers in Cell and Developmental Biology, 2021, 9, 707268.	1.8	41
902	Network model of pathology spread recapitulates neurodegeneration and selective vulnerability in Huntington's Disease. NeuroImage, 2021, 235, 118008.	2.1	12
903	Role of metals in Alzheimerâ€™s disease. Metabolic Brain Disease, 2021, 36, 1627-1639.	1.4	62
904	Investigating hypotheses of neurodegeneration by learning dynamical systems of protein propagation in the brain. NeuroImage, 2021, 235, 117980.	2.1	10
905	Microglia in Alzheimer's disease at single-cell level. Are there common patterns in humans and mice?. Journal of Experimental Medicine, 2021, 218, .	4.2	147
906	Transcription factors and chaperone proteins play a role in launching a faster response to heat stress and aggregation. Computational Biology and Chemistry, 2021, 93, 107534.	1.1	7

#	Article	IF	Citations
907	Imaging protein aggregates in the serum and cerebrospinal fluid in Parkinsonâ€™s disease. Brain, 2022, 145, 632-643.	3.7	20
908	Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimerâ€™s and other neurodegenerative diseases. Expert Review of Neurotherapeutics, 2021, 21, 949-967.	1.4	4
909	The chaperone HSPB1 prepares protein aggregates for resolubilization by HSP70. Scientific Reports, 2021, 11, 17139.	1.6	19
910	DAXX represents a new type of protein-folding enabler. Nature, 2021, 597, 132-137.	13.7	54
913	Accumulation of C-terminal cleaved tau is distinctly associated with cognitive deficits, synaptic plasticity impairment, and neurodegeneration in aged mice. GeroScience, 2022, 44, 173-194.	2.1	6
914	Microglial inclusions and neurofilament light chain release follow neuronal Î±-synuclein lesions in long-term brain slice cultures. Molecular Neurodegeneration, 2021, 16, 54.	4.4	20
915	Neuronal excitation/inhibition imbalance: core element of a translational perspective on Alzheimer pathophysiology. Ageing Research Reviews, 2021, 69, 101372.	5.0	90
916	Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimerâ€™s and Parkinsonâ€™s Diseases. International Journal of Molecular Sciences, 2021, 22, 9082.	1.8	38
917	Drosophila as a Model for Microbiota Studies of Neurodegeneration. Journal of Alzheimer's Disease, 2021, 84, 479-490.	1.2	10
918	Sirtuins as Potential Therapeutic Targets for Mitigating Neuroinflammation Associated With Alzheimerâ€™s Disease. Frontiers in Cellular Neuroscience, 2021, 15, 746631.	1.8	20
919	Structural and Functional Insights into Î±-Synuclein Fibril Polymorphism. Biomolecules, 2021, 11, 1419.	1.8	39
920	The neuromicrobiology of Parkinsonâ€™s disease: A unifying theory. Ageing Research Reviews, 2021, 70, 101396.	5.0	24
921	Is Multiple System Atrophy a Prion-like Disorder?. International Journal of Molecular Sciences, 2021, 22, 10093.	1.8	12
922	Inhibition of Staphylococcus aureus biofilm-forming functional amyloid by molecular tweezers. Cell Chemical Biology, 2021, 28, 1310-1320.e5.	2.5	15
923	Astrocytes in Neurodegenerative Diseases: A Perspective from Tauopathy and Î±-Synucleinopathy. Life, 2021, 11, 938.	1.1	13
924	Genetically encoded cell-death indicators (GEDI) to detect an early irreversible commitment to neurodegeneration. Nature Communications, 2021, 12, 5284.	5.8	13
925	Insulin and Insulin Resistance in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 9987.	1.8	97
926	Impact of Sterilization Methods on the Seeding Ability of Human Tau Proteopathic Seeds. Journal of Neuropathology and Experimental Neurology, 2021, 80, 912-921.	0.9	0

#	Article	IF	Citations
927	Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates. Scientific Reports, 2021, 11, 17977.	1.6	16
928	Tau secretion and propagation: Perspectives for potential preventive interventions in Alzheimer's disease and other tauopathies. Experimental Neurology, 2021, 343, 113756.	2.0	18
929	A importÃ¢ncia do equilÃbrio entre flexibilidade e estabilidade neuronal na formaÃ§Ã£o de memÃ³rias. Revistamultidisciplinar Com, 2021, 3, 5-11.	0.1	0
930	Brain aging mechanisms with mechanical manifestations. Mechanisms of Ageing and Development, 2021, 200, 111575.	2.2	57
931	Activity-dependent release of phosphorylated human tau from Drosophila neurons in primary culture. Journal of Biological Chemistry, 2021, 297, 101108.	1.6	4
932	Principles of brain aging: Status and challenges of modeling human molecular changes in mice. Ageing Research Reviews, 2021, 72, 101465.	5.0	7
934	Spreading of TDP-43 pathology via pyramidal tract induces ALS-like phenotypes in TDP-43 transgenic mice. Acta Neuropathologica Communications, 2021, 9, 15.	2.4	20
935	From Posttranslational Modifications to Disease Phenotype: A Substrate Selection Hypothesis in Neurodegenerative Diseases. International Journal of Molecular Sciences, 2021, 22, 901.	1.8	7
936	Network-constrained technique to characterize pathology progression rate in Alzheimerâ€™s disease. Brain Communications, 2021, 3, fcab144.	1.5	3
937	Design, Synthesis, and Activity Study of Cinnamic Acid Derivatives as Potent Antineuroinflammatory Agents. ACS Chemical Neuroscience, 2021, 12, 419-429.	1.7	11
938	Extracellular GAPDH Promotes Alzheimer Disease Progression by Enhancing Amyloid-Î² Aggregation and Cytotoxicity. , 2021, 12, 1223.		16
941	Drug Development for Neurodegenerative Diseases. , 2015, , 183-216.		5
942	The Expanding Role of RNA-Binding Proteins in Neurodegeneration. , 2019, , 373-403.		2
943	Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease. Advances in Experimental Medicine and Biology, 2019, 1184, 145-166.	0.8	11
944	Tau Prion-Like Propagation: State of theÂArt and Current Challenges. Advances in Experimental Medicine and Biology, 2019, 1184, 305-325.	0.8	47
945	Tau in Alzheimerâ€™s Disease: Pathological Alterations and an Attractive Therapeutic Target. Current Medical Science, 2020, 40, 1009-1021.	0.7	16
946	Amyloid structure. Essays in Biochemistry, 2014, 56, 1-10.	2.1	15
947	The role of fibril structure and surface hydrophobicity in secondary nucleation of amyloid fibrils. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 25272-25283.	3.3	58

#	Article	IF	Citations
948	Nanoelectrical characterization of individual exosomes secreted by AÎ²42-ingested cells using electrostatic force microscopy. Nanotechnology, 2021, 32, 025705.	1.3	7
964	Posttranslational modifications define course of prion strain adaptation and disease phenotype. Journal of Clinical Investigation, 2020, 130, 4382-4395.	3.9	19
965	ÃŸ-amyloid induces a dying-back process and remote trans-synaptic alterations in a microfluidic-based reconstructed neuronal network. Acta Neuropathologica Communications, 2014, 2, 145.	2.4	34
966	Puzzles in modern biology. IV. Neurodegeneration, localized origin and widespread decay. F1000Research, 2016, 5, 2537.	0.8	3
967	Genomic Characteristics of Genetic Creutzfeldt-Jakob Disease Patients with V180I Mutation and Associations with Other Neurodegenerative Disorders. PLoS ONE, 2016, 11, e0157540.	1.1	7
968	Bis(sulfosuccinimidyl) suberate (BS3) crosslinking analysis of the behavior of amyloid-Î² peptide in solution and in phospholipid membranes. PLoS ONE, 2017, 12, e0173871.	1.1	15
969	Formation and spreading of TDP-43 aggregates in cultured neuronal and glial cells demonstrated by time-lapse imaging. PLoS ONE, 2017, 12, e0179375.	1.1	36
970	Reversible unfolding of infectious prion assemblies reveals the existence of an oligomeric elementary brick. PLoS Pathogens, 2017, 13, e1006557.	2.1	29
971	Strains of Pathological Protein Aggregates in Neurodegenerative Diseases. Discoveries, 2017, 5, e78.	1.5	8
972	Transgenic Monkey Model of the Polyglutamine Diseases Recapitulating Progressive Neurological Symptoms. ENeuro, 2017, 4, ENEURO.0250-16.2017.	0.9	66
974	Protein Folding, Misfolding, Aggregation And Amyloid Formation: Mechanisms of AÎ² Oligomer Mediated Toxicities. Journal of Biochemistry and Molecular Biology Research, 2015, 1, 36-45.	0.3	3
975	AÎ² Plaques. Free Neuropathology, 2020, 1, .	2.4	21
976	New Insight in The Molecular Mechanisms of Neurodegenerative Disease. Indonesian Biomedical Journal, 2018, 10, 16.	0.2	3
977	Amyloid-Î² in the Cerebrospinal Fluid of APP Transgenic Mice Does not Show Prion-like Properties. Current Alzheimer Research, 2015, 12, 886-891.	0.7	3
978	Blood-Based Biomarkers of Alzheimers Disease: Diagnostic Algorithms and New Technologies. Current Alzheimer Research, 2016, 13, 450-464.	0.7	19
979	Advances in Studies on Stroke-Induced Secondary Neurodegeneration (SND) and Its Treatment. Current Topics in Medicinal Chemistry, 2020, 20, 1154-1168.	1.0	10
980	Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological Proteins Related to the Alzheimer's Disease. Current Neuropharmacology, 2018, 16, 758-768.	1.4	12
981	Protein Misfolding and Aggregation in Alzheimerâ€™s Disease and Type 2 Diabetes Mellitus. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1280-1293.	0.8	138

#	Article	IF	Citations
982	Iron Dysregulation and Inflammagens Related to Oral and Gut Health Are Central to the Development of Parkinsonâ€™s Disease. Biomolecules, 2021, 11, 30.	1.8	13
983	The N-terminus of the prion protein is a toxic effector regulated by the C-terminus. ELife, 2017, 6, .	2.8	68
984	Intrinsically aggregation-prone proteins form amyloid-like aggregates and contribute to tissue aging in Caenorhabditis elegans. ELife, 2019, 8, .	2.8	51
985	Differences in topological progression profile among neurodegenerative diseases from imaging data. ELife, 2019, 8, .	2.8	11
986	Stochastic yield catastrophes and robustness in self-assembly. ELife, 2020, 9, .	2.8	6
987	A gut bacterial amyloid promotes Î±-synuclein aggregation and motor impairment in mice. ELife, 2020, 9, .	2.8	251
988	Label-free photothermal disruption of cytotoxic aggregates rescues pathology in a C. elegans model of Huntingtonâ€™s disease. Scientific Reports, 2021, 11, 19732.	1.6	2
989	Tau Post-Translational Modifications: Potentiators of Selective Vulnerability in Sporadic Alzheimerâ€™s Disease. Biology, 2021, 10, 1047.	1.3	14
990	Utilizing 3D Arterial Spin Labeling to Identify Cerebrovascular Leak and Glymphatic Obstruction in Neurodegenerative Disease. Diagnostics, 2021, 11, 1888.	1.3	8
991	Abnormal Functional Brain Network in Parkinson's Disease and the Effect of Acute Deep Brain Stimulation. Frontiers in Neurology, 2021, 12, 715455.	1.1	2
992	Macroscopic modelling of Alzheimerâ€™s disease: difficulties and challenges. Brain Multiphysics, 2021, 2, 100040.	0.8	6
993	Current Status and Challenges of Stem Cell Treatment for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 84, 917-935.	1.2	8
994	Welcome to Advances in Rare Diseases. Advances in Rare Diseases, 2014, 01, .	1.0	0
995	Protein seeding in Alzheimerâ€™s disease and Parkinsonâ€™s disease: Similarities and differences. World Journal of Neurology, 2014, 4, 23.	0.6	0
996	Frequent and symmetric deposition of misfolded tau oligomers within presynaptic and postsynaptic terminals in AlzheimerÂ¿s disease. Acta Neuropathologica Communications, 2014, 2, 146.	2.4	60
997	Axonal Transport and Neurodegenerative Diseasesâ˜†. , 2015, , .		0
1000	Prions et transconformation protÃ©ique: une perspective historique. Bulletin De L'Academie Nationale De Medecine, 2015, 199, 787-796.	0.0	0
1002	Small Molecule-Assisted PET: Approaches to Imaging of Conformational Diseases of the Brain. World Journal of Neuroscience, 2017, 07, 106-139.	0.1	1

#	Article	IF	Citations
1009	MALDI Imaging Mass Spectrometry: Neurochemical Imaging of Proteins and Peptides. Neuromethods, 2019, , 179-197.	0.2	6
1019	Drug development against dementia based on understanding of molecular and cellular pathogenesis. Drug Delivery System, 2019, 34, 346-351.	0.0	0
1023	Protein aggregates carry non-genetic memory in bacteria after stresses. Biopolymers and Cell, 2020, 36, 409-422.	0.1	2
1024	Capturing nested information from disordered peptide phases. Peptide Science, 2021, 113, e24215.	1.0	2
1027	Surface effects on the degree of twist in amyloid fibril structures. Chemical Communications, 2020, 56, 3147-3150.	2.2	8
1028	Les protÃ©inopathies infectieuses de Parkinson et dâ€™Alzheimer. Bulletin De L'Academie Nationale De Medecine, 2020, 204, 224-231.	0.0	0
1031	A transglutaminase 2-like gene from sea cucumber Apostichopus japonicus mediates coelomocytes autophagy. Fish and Shellfish Immunology, 2021, 119, 602-612.	1.6	1
1032	Role of CPEB3 protein in learning and memory: new insights from synaptic plasticity. Aging, 2020, 12, 15169-15182.	1.4	13
1036	CHAPTER 7. Neuroinflammation and Oxidative Stress in Models of Parkinsonâ€™s Disease and Protein-Misfolding Disorders. Issues in Toxicology, 0, , 184-209.	0.2	1
1037	Identification and characterization of a compound from Cuminum cyminum essential oil with antifibrilation and cytotoxic effect. Research in Pharmaceutical Sciences, 2014, 9, 431-43.	0.6	5
1038	The Malignant Protein Puzzle. Cerebrum: the Dana Forum on Brain Science, 2016, 2016, .	0.1	0
1040	Neuroinflammation Induces Neurodegeneration. , 2016, 1, .		182
1041	Beta-catenin Forms Protein Aggregation at High Concentrations in HEK293TCells. Iranian Journal of Medical Sciences, 2017, 42, 66-72.	0.3	2
1042	Conditioning Against the Pathology of Parkinson's disease. Conditioning Medicine, 2018, 1, 143-162.	1.3	6
1043	Two-faced behavior of microglia in Alzheimerâ€™s disease. Nature Neuroscience, 2022, 25, 3-4.	7.1	20
1045	White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer's disease and frontotemporal dementia. Neurobiology of Aging, 2022, 111, 54-63.	1.5	22
1047	Current Psychological Approaches in Neurodegenerative Diseases. , 2022, , 1-29.		3
1048	Targeting disorders in unstructured and structured proteins in various diseases. Biophysical Chemistry, 2022, 281, 106742.	1.5	11

#	Article	IF	Citations
1049	Alzheimer: Wie man nach einer kausalen Therapie sucht. , 0, , .		0
1050	Biochemical Principles in Prion-Based Inheritance. Epigenomes, 2022, 6, 4.	0.8	6
1052	Inhibition of ceramide accumulation in AdipoR1â€“/â€“ mice increases photoreceptor survival and improves vision. JCI Insight, 2022, 7, .	2.3	12
1053	Molecular structure of an amyloid fibril formed by FUS low-complexity domain. IScience, 2022, 25, 103701.	1.9	19
1054	Regulation of neuronal autophagy and the implications in neurodegenerative diseases. Neurobiology of Disease, 2022, 162, 105582.	2.1	23
1055	Nasal Rifampicin Halts the Progression of Tauopathy by Inhibiting Tau Oligomer Propagation in Alzheimer Brain Extract-Injected Mice. Biomedicines, 2022, 10, 297.	1.4	7
1056	Cryo-EM demonstrates the in vitro proliferation of an ex vivo amyloid fibril morphology by seeding. Nature Communications, 2022, 13, 85.	5.8	15
1057	Sleep and circadian rhythms in Parkinsonâ€™s disease and preclinical models. Molecular Neurodegeneration, 2022, 17, 2.	4.4	32
1058	Air Pollution and the Risk of Parkinson's Disease: A Review. Movement Disorders, 2022, 37, 894-904.	2.2	28
1059	Cytotoxic tau released from lung microvascular endothelial cells upon infection with Pseudomonas aeruginosa promotes neuronal tauopathy. Journal of Biological Chemistry, 2022, 298, 101482.	1.6	14
1060	Detection of plasma AÎ² seeding activity by a newly developed analyzer for diagnosis of Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2022, 14, 21.	3.0	2
1061	The Ubiquitination-Dependent and -Independent Functions of Cereblon in Cancer and Neurological Diseases. Journal of Molecular Biology, 2022, 434, 167457.	2.0	5
1062	Role of exosomes in the pathogenesis of inflammation in Parkinsonâ€™s disease. Neural Regeneration Research, 2022, 17, 1898.	1.6	32
1063	Modeling seeding and neuroanatomic spread of pathology in amyotrophic lateral sclerosis. NeuroImage, 2022, 251, 118968.	2.1	5
1064	Approche clinique des troubles neurocognitifs des pathologies dÃ©gÃ©nÃ©ratives. La Presse MÃ©dicale Formation, 2022, 3, 57-57.	0.1	0
1065	Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain, 2022, 145, 584-595.	3.7	65
1066	Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia. Brain, 2023, 146, 321-336.	3.7	30
1067	Idiopathic normal pressure hydrocephalus-like MRI features in patients with progressive supranuclear palsy: a comparative case-control study. Neurological Research, 2022, 44, 807-813.	0.6	2

#	Article	IF	Citations
1068	The Digital Brain Bank, an open access platform for post-mortem imaging datasets. ELife, 2022, 11, .	2.8	22
1069	Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases. Cell, 2022, 185, 1346-1355.e15.	13.5	70
1070	Disrupted default mode network and executive control network are associated with depression severity on structural network. NeuroReport, 2022, 33, 227-235.	0.6	2
1071	Autophagy Alteration in ApoA-I Related Systemic Amyloidosis. International Journal of Molecular Sciences, 2022, 23, 3498.	1.8	3
1072	Tau pathology, metal dyshomeostasis and repetitive mild traumatic brain injury: an unexplored link paving the way for neurodegeneration. Journal of Neurotrauma, 2022, , .	1.7	7
1073	Proteins Do Not Replicate, They Precipitate: Phase Transition and Loss of Function Toxicity in Amyloid Pathologies. Biology, 2022, 11, 535.	1.3	14
1074	Intrathecal amyloidâ€beta oligomer administration increases tau phosphorylation in the medial temporal lobe in the African green monkey: A nonhuman primate model of Alzheimer's disease. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	5
1075	Propagation of tau and Î±-synuclein in the brain: therapeutic potential of the glymphatic system. Translational Neurodegeneration, 2022, 11, 19.	3.6	15
1076	Emerging Potential of Exosomal Non-coding RNA in Parkinsonâ€™s Disease: A Review. Frontiers in Aging Neuroscience, 2022, 14, 819836.	1.7	10
1078	Tissueâ€Scale Biomechanical Testing of Brain Tissue for the Calibration of Nonlinear Material Models. Current Protocols, 2022, 2, e381.	1.3	6
1079	Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis. Heart Failure Reviews, 2022, 27, 2187-2200.	1.7	11
1080	Modelling female physiology from head to Toe: Impact of sex hormones, menstrual cycle, and pregnancy. Journal of Theoretical Biology, 2022, 540, 111074.	0.8	13
1081	Structure-activity relationship of carbon nitride dots in inhibiting Tau aggregation. Carbon, 2022, 193, 1-16.	5.4	20
1082	Drug delivery of memantine with carbon dots for Alzheimerâ€™s disease: bloodâ€“brain barrier penetration and inhibition of tau aggregation. Journal of Colloid and Interface Science, 2022, 617, 20-31.	5.0	35
1083	Carbamylated Erythropoietin-Fc (CEPO-Fc) ameliorates Aβ25-35 induced neurotoxicity by modulating autophagy, apoptosis, and necroptosis in Alzheimer's Disease model rats. Physiology and Pharmacology, 2021, .	0.1	1
1084	Distinct patterns of progressive gray and white matter degeneration in amyotrophic lateral sclerosis. Human Brain Mapping, 2022, 43, 1519-1534.	1.9	7
1085	Examining the Ensembles of Amyloid-β Monomer Variants and Their Propensities to Form Fibers Using an Energy Landscape Visualization Method. Journal of Physical Chemistry B, 2022, 126, 93-99.	1.2	17
1086	Dysregulation of the Retromer Complex in Brain Endothelial Cells Results in Accumulation of Phosphorylated Tau. Journal of Inflammation Research, 2021, Volume 14, 7455-7465.	1.6	5

#	Article	IF	Citations
1087	The Myelinâ€Weighted Connectome in Parkinson's Disease. Movement Disorders, 2022, 37, 724-733.	2.2	10
1088	Acidic nanoparticles protect against Î±â€synucleinâ€induced neurodegeneration through the restoration of lysosomal function. Aging Cell, 2022, 21, e13584.	3.0	19
1089	The Role of the Gut Microbiota and Microbial Metabolites in the Pathogenesis of Alzheimerâ€™s Disease. CNS and Neurological Disorders - Drug Targets, 2023, 22, 577-598.	0.8	4
1090	Serpin Signatures in Prion and Alzheimerâ€™s Diseases. Molecular Neurobiology, 2022, 59, 3778-3799.	1.9	18
1091	Î±-synuclein as an emerging pathophysiological biomarker of Alzheimerâ€™s disease. Expert Review of Molecular Diagnostics, 2022, 22, 411-425.	1.5	4
1108	Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid Î² plaque formation in mice. Alzheimer's Research and Therapy, 2022, 14, 59.	3.0	57
1109	Nonlocal models in the analysis of brain neurodegenerative protein dynamics with application to Alzheimerâ€™s disease. Scientific Reports, 2022, 12, 7328.	1.6	9
1110	C9orf72 Hexanucleotide Repeat Expansion-Related Neuropathology Is Attenuated by Nasal Rifampicin in Mice. Biomedicines, 2022, 10, 1080.	1.4	2
1111	The chaperone Clusterin in neurodegenerationâ˜friend or foe?. BioEssays, 2022, 44, e2100287.	1.2	18
1112	Highly Specific and Sensitive Target Binding by the Humanized pS396-Tau Antibody hC10.2 Across a Wide Spectrum of Alzheimerâ€™s Disease and Primary Tauopathy Postmortem Brains. Journal of Alzheimer's Disease, 2022, 88, 207-228.	1.2	5
1113	Physiological and Pathological Roles of the Cytohesin Family in Neurons. International Journal of Molecular Sciences, 2022, 23, 5087.	1.8	3
1115	Biological aging processes underlying cognitive decline and neurodegenerative disease. Journal of Clinical Investigation, 2022, 132, .	3.9	74
1116	Charge detection mass spectrometry on human-amplified fibrils from different synucleinopathies. Chemical Communications, 2022, 58, 7192-7195.	2.2	1
1117	2D HP protein folding using quantum genetic algorithm. , 2022, , .		1
1118	The Relationships Among Metal Homeostasis, Mitochondria, and Locus Coeruleus in Psychiatric and Neurodegenerative Disorders: Potential Pathogenetic Mechanism and Therapeutic Implications. Cellular and Molecular Neurobiology, 2023, 43, 963-989.	1.7	4
1119	Conformational strains of pathogenic amyloid proteins in neurodegenerative diseases. Nature Reviews Neuroscience, 2022, 23, 523-534.	4.9	43
1121	Isotopeâ€labeled amyloidâ€Î² does not transmit to the brain in a prionâ€like manner after peripheral administration. EMBO Reports, 0, , .	2.0	7
1122	Influence of Ion Specificity and Concentration on the Conformational Transition of Intrinsically Disordered Sheep Prion Peptide. ChemPhysChem, 2022, 23, .	1.0	3

#	Article	IF	Citations
1123	Trans-channel fluorescence learning improves high-content screening for Alzheimerâ€™s disease therapeutics. Nature Machine Intelligence, 2022, 4, 583-595.	8.3	9
1124	Non-human primates in prion diseases. Cell and Tissue Research, 0, , .	1.5	4
1125	A toy model of misfolded protein aggregation and neural damage propagation in neurodegenerative diseases. International Journal of Non-Linear Mechanics, 2022, 144, 104083.	1.4	1
1127	Processus neurodÃ©gÃ©nÃ©ratifs etÂinflammation. , 2022, , 3-16.		0
1128	Cerebral AÎ² deposition in an AÎ²-precursor protein-transgenic rhesus monkey. Aging Brain, 2022, 2, 100044.	0.7	2
1129	Plasticity of Membrane Binding by the Central Region of Î±-Synuclein. Frontiers in Molecular Biosciences, 0, 9, .	1.6	5
1130	LRRK2 and Proteostasis in Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 6808.	1.8	5
1131	Proteomics for comprehensive characterization of extracellular vesicles in neurodegenerative disease. Experimental Neurology, 2022, 355, 114149.	2.0	5
1132	Molecular Dynamics Simulations of the Tau Amyloid Fibril Core Dimer at the Surface of a Lipid Bilayer Model: I. In Alzheimerâ€™s Disease. Journal of Physical Chemistry B, 2022, 126, 4849-4856.	1.2	10
1133	Preventive effects of arctigenin from Arctium lappa L against LPS-induced neuroinflammation and cognitive impairments in mice. Metabolic Brain Disease, 2022, 37, 2039-2052.	1.4	7
1134	Antiprion systems in yeast cooperate to cure or prevent the generation of nearly all [PSI ⁺] and [URE3] prions. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	9
1135	Heparan sulfate proteoglycans mediate prion-like Î±-synuclein toxicity in Parkinsonâ€™s in vivo models. Life Science Alliance, 2022, 5, e202201366.	1.3	11
1137	Parkinson disease and other synucleinopathies. , 2023, , 253-274.		0
1138	Seed-induced AÎ² deposition alters neuronal function and impairs olfaction in a mouse model of Alzheimerâ€™s disease. Molecular Psychiatry, 2022, 27, 4274-4284.	4.1	1
1139	Enriched environment ameliorates propagation of tau pathology and improves cognition in rat model of tauopathy. Frontiers in Aging Neuroscience, 0, 14, .	1.7	1
1141	Angiotensin converting enzyme inhibitor captopril prevents neuronal overexpression of amyloid-beta and alpha-synuclein in Drosophila melanogaster genetic models of neurodegenerative diseases. Tropical Freshwater Biology, 2022, 37, 21-28.	0.1	2
1142	Molecular Interaction Between Boron Tracedrug UTX-51 Derivatives and Bovine Serum Albumin: Application to an Analytical Model of AGEs Destruction by Thermal Neutron Irradiation. Anticancer Research, 2022, 42, 4017-4023.	0.5	0
1143	Interactions of amyloid coaggregates with biomolecules and its relevance to neurodegeneration. FASEB Journal, 2022, 36, .	0.2	11

#	Article	IF	Citations
1144	Simultaneous PET/MRI: The future gold standard for characterizing motor neuron diseaseâ€"A clinico-radiological and neuroscientific perspective. Frontiers in Neurology, 0, 13, .	1.1	3
1145	Direct Oral Anticoagulants (DOACs) for Therapeutic Targeting of Thrombin, a Key Mediator of Cerebrovascular and Neuronal Dysfunction in Alzheimerâ€™s Disease. Biomedicines, 2022, 10, 1890.	1.4	9
1147	Tracking the Progression and Influence of Beta-Amyloid Plaques Using Percolation Centrality and Collective Influence Algorithm: A Study Using PET Images. Annals of Neurosciences, 0, , 097275312211176.	0.9	0
1149	The glymphatic system: implications for drugs for central nervous system diseases. Nature Reviews Drug Discovery, 2022, 21, 763-779.	21.5	47
1151	Seed-induced AÎ² deposits in the corpus callosum disrupt white matter integrity in a mouse model of Alzheimerâ€™s disease. Frontiers in Cellular Neuroscience, 0, 16, .	1.8	1
1152	Î±-Synuclein Aggregation Intermediates form Fibril Polymorphs with Distinct Prion-like Properties. Journal of Molecular Biology, 2022, 434, 167761.	2.0	8
1153	How molecular imaging studies can disentangle disease mechanisms in age-related neurodegenerative disorders. , 2023, , 455-492.		0
1154	Biophysical elucidation of neural network and chemical regeneration of neural tissue. Biophysics and Physicobiology, 2022, 19, n/a.	0.5	0
1155	Post-COVID-19 Parkinsonism and Parkinsonâ€™s Disease Pathogenesis: The Exosomal Cargo Hypothesis. International Journal of Molecular Sciences, 2022, 23, 9739.	1.8	8
1156	Neuropathology and neuroanatomy of TDP-43 amyotrophic lateral sclerosis. Current Opinion in Neurology, 2022, 35, 660-671.	1.8	7
1157	Recombinant Mammalian Prions: The â€œCorrectlyâ€•Misfolded Prion Protein Conformers. Viruses, 2022, 14, 1940.	1.5	1
1158	Protein Homeostasis Dysregulation in Pathogenesis of Neurodegenerative Diseases. Molecular Biology, 2022, 56, 967-978.	0.4	2
1159	Mass Spectrometry and Machine Learning Reveal Determinants of Client Recognition by Antiamyloid Chaperones. Molecular and Cellular Proteomics, 2022, 21, 100413.	2.5	9
1160	Phase separation in immune regulation and immune-related diseases. Journal of Molecular Medicine, 2022, 100, 1427-1440.	1.7	3
1162	Behavioral and Molecular Effects of Thapsigargin-Induced Brain ER- Stress: Encompassing Inflammation, MAPK, and Insulin Signaling Pathway. Life, 2022, 12, 1374.	1.1	1
1163	The multiple faces of extracellular vesicles released by microglia: Where are we 10 years after?. Frontiers in Cellular Neuroscience, 0, 16, .	1.8	13
1165	Î±-synuclein buildup is alleviated via ESCRT-dependent endosomal degradation brought about by p38MAPK inhibition in cells expressing p25Î±. Journal of Biological Chemistry, 2022, 298, 102531.	1.6	3
1166	Na,K-ATPase Acts as a Beta-Amyloid Receptor Triggering Src Kinase Activation. Cells, 2022, 11, 2753.	1.8	3

#	Article	IF	Citations
1167	Environmental exposure to metals and the development of tauopathies, synucleinopathies, and TDP-43 proteinopathies: A systematic evidence map protocol. Environment International, 2022, 169, 107528.	4.8	4
1168	Seeding, maturation and propagation of amyloid Î²-peptide aggregates in Alzheimerâ€™s disease. Brain, 2022, 145, 3558-3570.	3.7	6
1169	Overexpression of mouse prion protein in transgenic mice causes a non-transmissible spongiform encephalopathy. Scientific Reports, 2022, 12, .	1.6	2
1170	Gerstmannâ€“StrÃ¤usslerâ€“Scheinker Disease with F198S Mutation Induces Independent Tau and Prion Protein Pathologies in Bank Voles. Biomolecules, 2022, 12, 1537.	1.8	2
1172	Head-to-Head Comparison of Tau-PET Radioligands for Imaging TDP-43 in Post-Mortem ALS Brain. Molecular Imaging and Biology, 2023, 25, 513-527.	1.3	8
1173	Dysfunctional microglia and tau pathology in Alzheimerâ€™s disease. Reviews in the Neurosciences, 2023, 34, 443-458.	1.4	8
1174	Single cell transcriptomic profiling of a neuron-astrocyte assembloid tauopathy model. Nature Communications, 2022, 13, .	5.8	14
1175	Association of Glial Activation and Î±-Synuclein Pathology in Parkinsonâ€™s Disease. Neuroscience Bulletin, 2023, 39, 479-490.	1.5	11
1176	Non-classical critical precipitates in a nucleation and growth regime: Reconciliation of simulation and experiment. Applied Physics Letters, 2022, 121, 184102.	1.5	2
1177	Manipulation of the dietâ€“microbiotaâ€“brain axis in Alzheimerâ€™s disease. Frontiers in Neuroscience, 0, 16, .	1.4	5
1179	Mesoscale connections and gene expression empower whole-brain modeling of Î±-synuclein spread, aggregation, and decay dynamics. Cell Reports, 2022, 41, 111631.	2.9	2
1180	Structureâ€“Propertyâ€“Activity Relationships in Carbon Dots. Journal of Physical Chemistry B, 2022, 126, 10777-10796.	1.2	8
1181	Inhibitory effects of fluorinated benzenesulfonamides on insulin fibrillation. International Journal of Biological Macromolecules, 2023, 227, 590-600.	3.6	1
1182	Endoplasmic Reticulum-Associated Degradation and Protein Quality Control. , 2016, , 773-788.		0
1183	Dual role of brain-derived extracellular vesicles in dementia-related neurodegenerative disorders: cargo of disease spreading signals and diagnostic-therapeutic molecules. Translational Neurodegeneration, 2022, 11, .	3.6	11
1184	Experimental evidence for temporal uncoupling of brain AÎ² deposition and neurodegenerative sequelae. Nature Communications, 2022, 13, .	5.8	6
1185	Connecting the Dots: Macromolecular Crowding and Protein Aggregation. Journal of Fluorescence, 2023, 33, 1-11.	1.3	15
1186	Sex-Specific Multiparameter Blood Test for the Early Diagnosis of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 15670.	1.8	6

#	Article	IF	Citations
1188	Synaptic degeneration in Alzheimer disease. Nature Reviews Neurology, 2023, 19, 19-38.	4.9	84
1189	Molecular Tweezers: Supramolecular Hosts with Broad-Spectrum Biological Applications. Pharmacological Reviews, 2023, 75, 263-308.	7.1	4
1190	Suppression of amyloid fibril formation by UV irradiation. Journal of Radiation Research and Applied Sciences, 2022, 15, 100484.	0.7	0
1191	Numbers of Mutations within Multicellular Bodies: Why It Matters. Axioms, 2023, 12, 12.	0.9	2
1192	The dynamics of three-dimensional chromatin organization and phase separation in cell fate transitions and diseases. Cell Regeneration, 2022, 11, .	1.1	4
1193	Spatially resolved transcriptomics reveals genes associated with the vulnerability of middle temporal gyrus in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2022, 10, .	2.4	23
1194	A structural basis for prion strain diversity. Nature Chemical Biology, 2023, 19, 607-613.	3.9	20
1195	Modulating amyloidsâ€™ formation path with sound energy. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	7
1196	Neurodegeneration in a novel invertebrate model system: Failed microtubuleâ€mediated cell adhesion and unraveling of macroglia. Journal of Comparative Neurology, 2023, 531, 618-638.	0.9	0
1197	The neuropathological mechanism on guanine-rich repeat expansion diseases. Folia Pharmacologica Japonica, 2023, 158, 30-33.	0.1	0
1198	Cross interactions between Apolipoprotein E and amyloid proteins in neurodegenerative diseases. Computational and Structural Biotechnology Journal, 2023, 21, 1189-1204.	1.9	4
1199	Untangling the Role of TREM2 in Conjugation with Microglia in Neuronal Dysfunction: A Hypothesis on a Novel Pathway in the Pathophysiology of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2023, 94, S319-S333.	1.2	4
1200	Functional and neuropathological changes induced by injection of distinct alpha-synuclein strains: A pilot study in non-human primates. Neurobiology of Disease, 2023, 180, 106086.	2.1	3
1201	Protein Misfolding and Aggregation in Proteinopathies: Causes, Mechanism and Cellular Response. Diseases (Basel, Switzerland), 2023, 11, 30.	1.0	9
1202	Alzheimerâ€™s disease as a fundamental disease of information processing systems: An information theory perspective. Frontiers in Neuroscience, 0, 17, .	1.4	1
1203	Vaccines for prion diseases: a realistic goal?. Cell and Tissue Research, 2023, 392, 367-392.	1.5	1
1204	Î±-Synuclein Conformational Strains as Drivers of Phenotypic Heterogeneity in Neurodegenerative Diseases. Journal of Molecular Biology, 2023, 435, 168011.	2.0	7
1205	Conformational Dynamics of an Î±-Synuclein Fibril upon Receptor Binding Revealed by Insensitive Nuclei Enhanced by Polarization Transfer-Based Solid-State Nuclear Magnetic Resonance and Cryo-Electron Microscopy. Journal of the American Chemical Society, 2023, 145, 4473-4484.	6.6	12

#	Article	IF	Citations
1206	Hallmarks of neurodegenerative diseases. Cell, 2023, 186, 693-714.	13.5	222
1207	Front Propagation and Arrival Times in Networks with Application to Neurodegenerative Diseases. SIAM Journal on Applied Mathematics, 2023, 83, 194-224.	0.8	2
1208	Extracellular protein homeostasis in neurodegenerative diseases. Nature Reviews Neurology, 0, , .	4.9	3
1209	Microscopic Understanding of the Conformational Stability of the Aggregated Nonamyloid Î² Components of Î±-Synuclein. Journal of Chemical Information and Modeling, 2023, 63, 1542-1555.	2.5	0
1210	Comprehensive Perspective Towards the Management of Proteinopathies by Elucidating Protein Misfolding and Aggregation. CNS and Neurological Disorders - Drug Targets, 2024, 23, 153-180.	0.8	1
1211	EEG resting-state networks in Alzheimerâ€™s disease associated with clinical symptoms. Scientific Reports, 2023, 13, .	1.6	4
1212	Protein amyloid aggregate: Structure and function. Aggregate, 2023, 4, .	5.2	5
1213	Mass Spectrometry Imaging in Alzheimer's Disease. Brain Connectivity, 2023, 13, 319-333.	0.8	4
1214	Monoclonal antibody Y01 prevents tauopathy progression induced by lysine 280â€“acetylated tau in cell and mouse models. Journal of Clinical Investigation, 2023, 133, .	3.9	4
1215	Mast Cell Proteases Cleave Prion Proteins and a Recombinant Ig against PrP Can Activate Human Mast Cells. Journal of Immunology, 2023, 210, 1447-1458.	0.4	0
1216	Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy. Pharmaceutics, 2023, 15, 1129.	2.0	3
1218	Early Alterations of RNA Binding Protein (RBP) Homeostasis and ER Stress-Mediated Autophagy Contributes to Progressive Retinal Degeneration in the rd10 Mouse Model of Retinitis Pigmentosa (RP). Cells, 2023, 12, 1094.	1.8	5
1219	In silico investigation of the structural stability as the origin of the pathogenicity of Î± -synuclein protofibrils. Journal of Biomolecular Structure and Dynamics, 2023, 41, 14103-14115.	2.0	1
1220	Cascade autohydrolysis of Alzheimer's AÎ² peptides. Chemical Science, 2023, 14, 4986-4996.	3.7	1
1221	The Î±-Synuclein Monomer May Have Different Misfolding Mechanisms in the Induction of Î±-Synuclein Fibrils with Different Polymorphs. Biomolecules, 2023, 13, 682.	1.8	0
1222	Attenuation of Î±-synuclein aggregation by catalytic photo-oxygenation. Chemical Communications, 2023, 59, 5745-5748.	2.2	2
1223	Long term worsening of amyloid pathology, cerebral function, and cognition after a single inoculation of beta-amyloid seeds with Osaka mutation. Acta Neuropathologica Communications, 2023, 11, .	2.4	0
1239	Clinical relevance of animal models in aging-related dementia research. Nature Aging, 2023, 3, 481-493.	5.3	5

#	Article	IF	Citations
1252	Current Psychological Approaches in Neurodegenerative Diseases. , 2023, , 261-289.		0
1253	Noninfectious Disease Vaccines. , 2023, , 736-746.e4.		0
1258	Connectome-based modelling of neurodegenerative diseases: towards precision medicine and mechanistic insight. Nature Reviews Neuroscience, 2023, 24, 620-639.	4.9	9
1259	Copper trafficking system in cells: insights into coordination chemistry and toxicity. Dalton Transactions, 0, , .	1.6	0
1266	Molecular pathology of neurodegenerative diseases by cryo-EM of amyloids. Nature, 2023, 621, 701-710.	13.7	18
1269	Decoding the Cellular Trafficking of Prion-like Proteins in Neurodegenerative Diseases. Neuroscience Bulletin, 2024, 40, 241-254.	1.5	0
1285	Glucose, glycolysis, and neurodegenerative disorders. , 2024, , 333-384.		0
1287	Risk of Parkinsonâ€™s disease in hepatitis B and C populations: a systematic review and meta-analysis. Journal of Neural Transmission, 0, , .	1.4	0
1288	Infrared Nanospectroscopy and Terahertz Irradiation of Pathological Protein Aggregates. , 2023, , .		0
1302	Data-driven modelling of neurodegenerative disease progression: thinking outside the black box. Nature Reviews Neuroscience, 2024, 25, 111-130.	4.9	0
1307	Amyloids as endogenous toxicants in neurodegenerative diseases. , 2024, , 1059-1081.		0
1309	Mismatch between clinically defined classification of ALS stage and the burden of cerebral pathology. Journal of Neurology, 2024, 271, 2547-2559.	1.8	0
1311	Evidence for iatrogenic transmission of Alzheimerâ€™s disease. Nature Medicine, 2024, 30, 344-345.	15.2	0